Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1
value | Author stringclasses 1
value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
38200.0 | 2019-08-23 00:00:00 UTC | Canopy Growth Stock Is Short on Fundamentals, But High on Potential | ACB | https://www.nasdaq.com/articles/canopy-growth-stock-is-short-on-fundamentals-but-high-on-potential-2019-08-23 | nan | nan | You don’t have to look far to see evidence that publicly traded marijuana companies are incredibly volatile. And that assessment is the same for the top players like Canopy Growth (NYSE:). Just in this month alone, Canopy Growth stock has dropped nearly 23%. And since the end of April, shares have shed slightly more th... | According to an Associated Press report on the subject, goodwill is the that companies place on a bought-out organization’s actual assets, such as property, plants and equipment. Moreover, the Associated Press prepared a great argument for why investors should fear blue-chip S&P 500 companies with excessive premiums fo... | And that assessment is the same for the top players like Canopy Growth (NYSE:). Why Goodwill Isn’t So Bad for CGC Stock Williams makes a compelling argument why you should avoid Canopy Growth stock. But with Canopy Growth stock, we don’t know what the potential limits are. | Why Goodwill Isn’t So Bad for CGC Stock Williams makes a compelling argument why you should avoid Canopy Growth stock. But with Canopy Growth stock, we don’t know what the potential limits are. Canopy Growth Stock Is All About the Reach At the end of the day, here’s why Canopy Growth stock and its ilk like Aurora Canna... | Why Goodwill Isn’t So Bad for CGC Stock Williams makes a compelling argument why you should avoid Canopy Growth stock. But with Canopy Growth stock, we don’t know what the potential limits are. Canopy Growth Stock Is All About the Reach At the end of the day, here’s why Canopy Growth stock and its ilk like Aurora Canna... |
38201.0 | 2019-08-23 00:00:00 UTC | 3 Pot Stocks With a Huge International Presence | ACB | https://www.nasdaq.com/articles/3-pot-stocks-with-a-huge-international-presence-2019-08-23 | nan | nan | The marijuana industry is budding before Wall Street's and investor's eyes, and it's no surprise that North America is in full focus.
To our north, Canada is preparing for marijuana legalization 2.0. Having already legalized and launched recreational cannabis sales on Oct. 17, 2018, Health Canada plans to begin enforci... | Aurora Cannabis: 25 countries (including Canada) Hands-down, there's no marijuana stock that can hold a candle to the aggressive international expansion that Aurora Cannabis (NYSE: ACB) brings to the table. In the meantime, Canopy Growth has acquired intellectual property company ebbu in Colorado, was awarded a hemp-pr... | Aurora Cannabis: 25 countries (including Canada) Hands-down, there's no marijuana stock that can hold a candle to the aggressive international expansion that Aurora Cannabis (NYSE: ACB) brings to the table. Canopy Growth: 16 countries (including Canada) The largest marijuana stock in the world, Canopy Growth (NYSE: CGC... | Aurora Cannabis: 25 countries (including Canada) Hands-down, there's no marijuana stock that can hold a candle to the aggressive international expansion that Aurora Cannabis (NYSE: ACB) brings to the table. Canopy Growth: 16 countries (including Canada) The largest marijuana stock in the world, Canopy Growth (NYSE: CGC... | Aurora Cannabis: 25 countries (including Canada) Hands-down, there's no marijuana stock that can hold a candle to the aggressive international expansion that Aurora Cannabis (NYSE: ACB) brings to the table. Including Canada, Tilray supplies cannabis, or conducts research, in 13 countries worldwide. The most important t... |
38202.0 | 2019-08-22 00:00:00 UTC | When Exactly Will Aurora Cannabis Stock’s Downtrend End? | ACB | https://www.nasdaq.com/articles/when-exactly-will-aurora-cannabis-stocks-downtrend-end-2019-08-22 | nan | nan | Aurora Cannabis (NYSE:) is stuck in a downward trajectory in the stock markets.
Source: ElRoi / Shutterstock.com
Weak quarterly earnings from Tilray (NASDAQ:) and a regulatory violation from CannTrust Holdings (NYSE:) are scaring investors away from the cannabis sector. When Aurora reports its quarterly results on Sept... | Even though ACB stock fell from the $10 high in March to the $5.80 range recently, the markets expect strong revenue growth. Canopy’s Q1 Miss Hurts ACB Stock On Aug. 15, Canopy Growth (NYSE:) reported an EBITDA loss of $92 million CAD in the first quarter. My Takeaway on ACB Stock Shorts have the upper hand on Aurora C... | Canopy’s Q1 Miss Hurts ACB Stock On Aug. 15, Canopy Growth (NYSE:) reported an EBITDA loss of $92 million CAD in the first quarter. Even though ACB stock fell from the $10 high in March to the $5.80 range recently, the markets expect strong revenue growth. My Takeaway on ACB Stock Shorts have the upper hand on Aurora C... | Even though ACB stock fell from the $10 high in March to the $5.80 range recently, the markets expect strong revenue growth. Canopy’s Q1 Miss Hurts ACB Stock On Aug. 15, Canopy Growth (NYSE:) reported an EBITDA loss of $92 million CAD in the first quarter. My Takeaway on ACB Stock Shorts have the upper hand on Aurora C... | Canopy’s Q1 Miss Hurts ACB Stock On Aug. 15, Canopy Growth (NYSE:) reported an EBITDA loss of $92 million CAD in the first quarter. My Takeaway on ACB Stock Shorts have the upper hand on Aurora Cannabis stock for the time being. Even though ACB stock fell from the $10 high in March to the $5.80 range recently, the mark... |
38203.0 | 2019-08-22 00:00:00 UTC | Will Hexo Stock Be Around for the Long Haul? | ACB | https://www.nasdaq.com/articles/will-hexo-stock-be-around-for-the-long-haul-2019-08-22 | nan | nan | When it comes to Canadian cannabis companies, Hexo (NYSE:) doesn’t always get the recognition it deserves. Hexo stock is often seen as the little brother to bigger players like Aurora Cannabis (NYSE:ACB) and Canopy Growth (NYSE:).
Source: Shutterstock
But if you’re looking to get in at the ground floor with a growing... | Hexo stock is often seen as the little brother to bigger players like Aurora Cannabis (NYSE:ACB) and Canopy Growth (NYSE:). Source: Shutterstock But if you’re looking to get in at the ground floor with a growing cannabis company, HEXO isn’t a bad option. And most recently, Canopy Growth released an abysmal earnings rep... | Hexo stock is often seen as the little brother to bigger players like Aurora Cannabis (NYSE:ACB) and Canopy Growth (NYSE:). And most recently, Canopy Growth released an abysmal earnings report showing that the company isn’t as profitable as many investors believed. Hexo Stock Isn’t Yet Profitable Hexo’s most recent ear... | Hexo stock is often seen as the little brother to bigger players like Aurora Cannabis (NYSE:ACB) and Canopy Growth (NYSE:). Hexo Stock Isn’t Yet Profitable Hexo’s most recent earnings report showed that the company achieved huge growth over the past year. However, like many cannabis companies, Hexo is not yet profitabl... | Hexo stock is often seen as the little brother to bigger players like Aurora Cannabis (NYSE:ACB) and Canopy Growth (NYSE:). Hexo Stock Isn’t Yet Profitable Hexo’s most recent earnings report showed that the company achieved huge growth over the past year. However, like many cannabis companies, Hexo is not yet profitabl... |
38204.0 | 2019-08-22 00:00:00 UTC | Why Aurora Cannabis May Have Made a Big Mistake By Not Partnering With a Beverage Company | ACB | https://www.nasdaq.com/articles/why-aurora-cannabis-may-have-made-a-big-mistake-by-not-partnering-with-a-beverage-company | nan | nan | Cannabis-infused beverages could soon be a big hit. Being able to drink a beverage, get a buzz, and not be hungover the next day could prove to be an easy sell to people who consume alcohol. While the segment hasn't taken off in the U.S. where beverages still represent a very small fraction of cannabis sales, that migh... | One company that isn't a believer There haven't been many big deals involving the beverage industry and marijuana companies thus far, and one striking omission is Aurora Cannabis (NYSE: ACB). For beer makers, it presents a great opportunity to take advantage of the fast-growing cannabis industry and a way to give their... | One company that isn't a believer There haven't been many big deals involving the beverage industry and marijuana companies thus far, and one striking omission is Aurora Cannabis (NYSE: ACB). Industry giant Canopy Growth (NYSE: CGC) partnered with big brewer Constellation Brands (NYSE: STZ) and Hexo Corp (NYSE: HEXO) a... | One company that isn't a believer There haven't been many big deals involving the beverage industry and marijuana companies thus far, and one striking omission is Aurora Cannabis (NYSE: ACB). It's going to be the first time some of the big players in the beverage industry take a crack at producing cannabis-infused drin... | One company that isn't a believer There haven't been many big deals involving the beverage industry and marijuana companies thus far, and one striking omission is Aurora Cannabis (NYSE: ACB). The Canadian market will be an important one because for cannabis-infused beverages, those products will be legal across the cou... |
38205.0 | 2019-08-22 00:00:00 UTC | Down 25% in a Month, CGC Stock Could Fall Further | ACB | https://www.nasdaq.com/articles/down-25-in-a-month-cgc-stock-could-fall-further-2019-08-22 | nan | nan | Canopy Growth (NYSE:) stock has taken a pounding. Shares are down nearly 25% in the past month, from $35.40 per share to $26.57 per share. The investor exodus from marijuana stocks has been brutal.
Source: Shutterstock
With excess supply outgunning demand, it’s no wonder the bull case for pot stocks is tough to justify... | ACB trades at an EV/Sales ratio of 48.2 In terms of other peers in the “cannabisphere,” Cronos Group (NASDAQ:) continues to trade at a high valuation (EV/Sales of 150.7). Source: Shutterstock With excess supply outgunning demand, it’s no wonder the bull case for pot stocks is tough to justify. Overestimating demand for... | ACB trades at an EV/Sales ratio of 48.2 In terms of other peers in the “cannabisphere,” Cronos Group (NASDAQ:) continues to trade at a high valuation (EV/Sales of 150.7). Valuation: Canopy Growth Stock Still Frothy Canopy Growth stock currently trades at a Enterprise Value/Sales (EV/Sales) ratio of 32.2. CGC Stock Dilu... | ACB trades at an EV/Sales ratio of 48.2 In terms of other peers in the “cannabisphere,” Cronos Group (NASDAQ:) continues to trade at a high valuation (EV/Sales of 150.7). Valuation: Canopy Growth Stock Still Frothy Canopy Growth stock currently trades at a Enterprise Value/Sales (EV/Sales) ratio of 32.2. With the recen... | ACB trades at an EV/Sales ratio of 48.2 In terms of other peers in the “cannabisphere,” Cronos Group (NASDAQ:) continues to trade at a high valuation (EV/Sales of 150.7). With the recent beat-down of Canopy Growth stock, shares are now a bargain compared to Aurora Cannabis. CGC Stock Dilution Risks Continue The company... |
38206.0 | 2019-08-22 00:00:00 UTC | Aurora Cannabis Doubles Down on U.S. CBD Market | ACB | https://www.nasdaq.com/articles/aurora-cannabis-doubles-down-on-u.s.-cbd-market-2019-08-22 | nan | nan | Aurora Cannabis (NYSE:) is continuing to spread its bets across product lines and markets far and wide. With a market cap now standing at $5.9 billion, the Edmonton, Canada-based marijuana stock is the second-largest cannabis company in the sector just behind Canopy Growth (NYSE:) of $9.25 billion.
Source: Shutterstock... | Size and ownership of distribution channels should allow ACB stock to focus on the highest margin products, notably branded medical marijuana. Despite news of the expansion, ACB stock closed down slightly and is now trading at $5.84, well off its 52-week high of $12.52. Certainly, investors have cooled off to ACB stock... | Here are three key reasons why ACB is a good long-term play: Aurora Cannabis Has Rock-Bottom Production Costs Aurora Cannabis has certainly been on an acquisition binge since it was first founded in 2006. ACB Stock Owns the Supply Chain and Creates Brand Equity ACB may be the leader among in terms of focusing on the hi... | Here are three key reasons why ACB is a good long-term play: Aurora Cannabis Has Rock-Bottom Production Costs Aurora Cannabis has certainly been on an acquisition binge since it was first founded in 2006. The acquisition of Hempco was just the latest in a string of ACB stock acquiring more production assets, including ... | Here are three key reasons why ACB is a good long-term play: Aurora Cannabis Has Rock-Bottom Production Costs Aurora Cannabis has certainly been on an acquisition binge since it was first founded in 2006. The U.S. CBD Market Is Already Alive and Kicking The most important reason for ACB’s acquisition of Hempco may be t... |
38207.0 | 2019-08-22 00:00:00 UTC | When Will the Big Canadian Cannabis Producers Become Profitable? | ACB | https://www.nasdaq.com/articles/when-will-the-big-canadian-cannabis-producers-become-profitable-2019-08-22 | nan | nan | You'll hear most of the big Canadian cannabis producers talk a lot about revenue growth. However, it's a different story when it comes to profits. In most cases, any reported profit for one of the five biggest Canadian producers will come with an asterisk: a paper profit fueled by a one-time gain rather than true opera... | Here are the most likely time frames for Aphria (NYSE: APHA), Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), Cronos Group (NASDAQ: CRON), and Tilray (NASDAQ: TLRY) to operate in the black. Instead, the company's profit stemmed primarily from its acquisition earlier this year of German medical cannabis and phar... | Here are the most likely time frames for Aphria (NYSE: APHA), Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), Cronos Group (NASDAQ: CRON), and Tilray (NASDAQ: TLRY) to operate in the black. The company reported net income of 15.8 million Canadian dollars, or CA$0.05 per share, in its fourth quarter ending May 3... | Here are the most likely time frames for Aphria (NYSE: APHA), Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), Cronos Group (NASDAQ: CRON), and Tilray (NASDAQ: TLRY) to operate in the black. In most cases, any reported profit for one of the five biggest Canadian producers will come with an asterisk: a paper prof... | Here are the most likely time frames for Aphria (NYSE: APHA), Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), Cronos Group (NASDAQ: CRON), and Tilray (NASDAQ: TLRY) to operate in the black. Aurora Cannabis Aurora Cannabis isn't anywhere close to being profitable at this point. While Aphria is already profitable... |
38208.0 | 2019-08-21 00:00:00 UTC | New Study Shows 14% of Americans Use CBD | ACB | https://www.nasdaq.com/articles/new-study-shows-14-of-americans-use-cbd-2019-08-21 | nan | nan | Fourteen percent of Americans personally use products containing cannabidiol (CBD), according to a recent Gallup Poll. Meanwhile, 85% of people in the U.S. are either not yet familiar with the cannabis-derived ingredient or do not currently use it.
Cannabidiol is a nonpsychoactive component of the cannabis plant. Unlik... | Aurora Cannabis (NYSE: ACB), the leading cannabis producer by peak capacity, is also moving aggressively into the CBD arena. Notable suppliers include Charlotte's Web Holdings (OTC: CWBHF), which produces a variety of CBD-based wellness products such as oils, capsules, and topical lotions. Aurora Cannabis plans to inte... | Aurora Cannabis (NYSE: ACB), the leading cannabis producer by peak capacity, is also moving aggressively into the CBD arena. Fourteen percent of Americans personally use products containing cannabidiol (CBD), according to a recent Gallup Poll. Charlotte's Web recently struck a deal with grocery titan Kroger, which will... | Aurora Cannabis (NYSE: ACB), the leading cannabis producer by peak capacity, is also moving aggressively into the CBD arena. Charlotte's Web is the leading global brand for hemp-derived CBD by market share, and the company is attempting to widen its lead by increasing its hemp production and broadening its retail distr... | Aurora Cannabis (NYSE: ACB), the leading cannabis producer by peak capacity, is also moving aggressively into the CBD arena. Not to be outdone, Canopy Growth (NYSE: CGC), the largest cannabis company by market capitalization, is strengthening its hemp and CBD production capabilities in the U.S. The Motley Fool recommen... |
38209.0 | 2019-08-21 00:00:00 UTC | 10 Marijuana Stocks That Could See 100% Gains, If Not More | ACB | https://www.nasdaq.com/articles/10-marijuana-stocks-that-could-see-100-gains-if-not-more-2019-08-21 | nan | nan | The past several months haven’t been particularly kind to cannabis stocks, as the hope (and hype) of the long-term potential collides with short-term reality. That is, most of these companies have spent heavily to take the lead in a highly contested race, but don’t yet have the scale needed to drive actual profits.
Tha... | Aurora Cannabis (ACB) Source: Shutterstock Canopy Growth may be best known, for better or worse, as a rapid-fire buyer of smaller cannabis outfits with the aim of building a large conglomerate. With a market cap of nearly $1 billion and $86 million worth of revenue for its past four reported quarters, Charlotte’s Web H... | Aurora Cannabis (ACB) Source: Shutterstock Canopy Growth may be best known, for better or worse, as a rapid-fire buyer of smaller cannabis outfits with the aim of building a large conglomerate. With a market cap of nearly $1 billion and $86 million worth of revenue for its past four reported quarters, Charlotte’s Web H... | Aurora Cannabis (ACB) Source: Shutterstock Canopy Growth may be best known, for better or worse, as a rapid-fire buyer of smaller cannabis outfits with the aim of building a large conglomerate. Cara Therapeutics (CARA) Source: Shutterstock As was the case with GW Pharmaceuticals, Cara Therapeutics (NASDAQ:) has largely... | Aurora Cannabis (ACB) Source: Shutterstock Canopy Growth may be best known, for better or worse, as a rapid-fire buyer of smaller cannabis outfits with the aim of building a large conglomerate. It already has one such partner: Molson Coors Brewing (NYSE:) is looking to build a cannabis beverage brand with Hexo. It’s no... |
38210.0 | 2019-08-21 00:00:00 UTC | 3 Compelling Catalysts for Aurora Cannabis Stock | ACB | https://www.nasdaq.com/articles/3-compelling-catalysts-for-aurora-cannabis-stock-2019-08-21 | nan | nan | I’m going to be blunt straight off the bat. Although the topic of the day is Aurora Cannabis (NYSE:), we can essentially lump all the major marijuana players together. That’s what the markets are doing and for good reason. At the end of the day, ACB stock is a race against time.
What do I mean by this? Simply, we know ... | At the end of the day, ACB stock is a race against time. One of the main criticisms of ACB stock and its ilk is that the underlying company is expanding aggressively. And that’s why I’m using the racing analogy for ACB stock. | Here are three reasons why: Harvard Research Offers Groundbreaking Medical Potential for ACB Stock Pancreatic cancer is among the nastiest of all cancers, imposing a very low survival rate. At the end of the day, ACB stock is a race against time. One of the main criticisms of ACB stock and its ilk is that the underlyin... | Here are three reasons why: Harvard Research Offers Groundbreaking Medical Potential for ACB Stock Pancreatic cancer is among the nastiest of all cancers, imposing a very low survival rate. At the end of the day, ACB stock is a race against time. One of the main criticisms of ACB stock and its ilk is that the underlyin... | At the end of the day, ACB stock is a race against time. One of the main criticisms of ACB stock and its ilk is that the underlying company is expanding aggressively. And that’s why I’m using the racing analogy for ACB stock. |
38211.0 | 2019-08-21 00:00:00 UTC | 4 of the Most Efficient Marijuana Stocks | ACB | https://www.nasdaq.com/articles/4-of-the-most-efficient-marijuana-stocks-2019-08-21 | nan | nan | The marijuana industry projects as a big-money business. Already on track for more than $14 billion in legal global sales in 2019, various Wall Street forecasts have opined that cannabis sales could hit $50 billion to $200 billion by the end of the next decade. That, presumably, leaves plenty of room for industry expan... | Aurora Cannabis Last, but not least, is the largest marijuana producer in the world, Aurora Cannabis (NYSE: ACB). Flowr, which has its Kelowna campus in British Columbia laser-focused on producing premium and ultra-premium dried flower, is working hand-in-hand with Scotts Miracle-Gro's subsidiary Hawthorne Gardening to... | Aurora Cannabis Last, but not least, is the largest marijuana producer in the world, Aurora Cannabis (NYSE: ACB). Nevertheless, there aren't any other major Canadian growers (i.e., producing north of 100,000 kilos a year) projected to yield north of 200 grams per square foot. Even though it's not going to rival Califor... | Aurora Cannabis Last, but not least, is the largest marijuana producer in the world, Aurora Cannabis (NYSE: ACB). The company is developing 150,000 square feet of outdoor grow adjacent to Kelowna, 189,000 square feet (in aggregate) in 42 greenhouses (also adjacent to Kelowna), and recently purchased the remaining stake... | Aurora Cannabis Last, but not least, is the largest marijuana producer in the world, Aurora Cannabis (NYSE: ACB). The problem is that there's a veritable laundry list of marijuana stocks to choose from, with new pot stocks coming to market on a fairly regular basis. Nevertheless, there aren't any other major Canadian g... |
38212.0 | 2019-08-20 00:00:00 UTC | The 10 Best Marijuana Stocks to Buy Now | ACB | https://www.nasdaq.com/articles/the-10-best-marijuana-stocks-to-buy-now-2019-08-20 | nan | nan | The second full week of August 2019 might go down in the history books as a turning point. This was when the benchmark Dow Jones index absorbed an 800-point drop, the worst day so far this year. Naturally, the volatility impacted already beleaguered marijuana stocks.
In my view, the cannabis market suffered from a two-... | Here are the ten best marijuana stocks to buy now: Aurora Cannabis (ACB) Aurora Cannabis (NYSE:) is easily one of the top names among marijuana stocks. However, the recent price action for ACB stock belies its reputation. Why such a dour response toward ACB stock? | Here are the ten best marijuana stocks to buy now: Aurora Cannabis (ACB) Aurora Cannabis (NYSE:) is easily one of the top names among marijuana stocks. However, the recent price action for ACB stock belies its reputation. Why such a dour response toward ACB stock? | Here are the ten best marijuana stocks to buy now: Aurora Cannabis (ACB) Aurora Cannabis (NYSE:) is easily one of the top names among marijuana stocks. However, the recent price action for ACB stock belies its reputation. Why such a dour response toward ACB stock? | Here are the ten best marijuana stocks to buy now: Aurora Cannabis (ACB) Aurora Cannabis (NYSE:) is easily one of the top names among marijuana stocks. However, the recent price action for ACB stock belies its reputation. Why such a dour response toward ACB stock? |
38213.0 | 2019-08-19 00:00:00 UTC | What Happened in the Stock Market Today | ACB | https://www.nasdaq.com/articles/what-happened-in-the-stock-market-today-2019-08-19 | nan | nan | Major benchmarks continued rebounding from jitters over trade and economic weakness on Monday, and the Dow Jones Industrial Average (DJINDICES: ^DJI) and the S&P 500 (SNPINDEX: ^GSPC) posted broad-based gains. The energy sector led the market as crude oil futures rose 2.5%, with technology and Chinese stocks performing... | As for individual stocks, Estee Lauder (NYSE: EL) hit all-time highs after reporting beautiful results, and Aurora Cannabis (NYSE: ACB) closed an acquisition and announced a new business unit. Major benchmarks continued rebounding from jitters over trade and economic weakness on Monday, and the Dow Jones Industrial Ave... | As for individual stocks, Estee Lauder (NYSE: EL) hit all-time highs after reporting beautiful results, and Aurora Cannabis (NYSE: ACB) closed an acquisition and announced a new business unit. Healthy China sales lift up Estee Lauder's results Cosmetics company Estee Lauder announced a strong fiscal fourth quarter and ... | As for individual stocks, Estee Lauder (NYSE: EL) hit all-time highs after reporting beautiful results, and Aurora Cannabis (NYSE: ACB) closed an acquisition and announced a new business unit. Healthy China sales lift up Estee Lauder's results Cosmetics company Estee Lauder announced a strong fiscal fourth quarter and ... | As for individual stocks, Estee Lauder (NYSE: EL) hit all-time highs after reporting beautiful results, and Aurora Cannabis (NYSE: ACB) closed an acquisition and announced a new business unit. The company expects continued sales gains and cost discipline to result in a healthy jump in profit in 2020, forecasting adjust... |
38214.0 | 2019-08-19 00:00:00 UTC | Aurora Cannabis Closes on Its Acquisition of Hempco Food and Fiber | ACB | https://www.nasdaq.com/articles/aurora-cannabis-closes-on-its-acquisition-of-hempco-food-and-fiber-2019-08-20 | nan | nan | Aurora Cannabis (NYSE: ACB) is expanding its empire.
The marijuana titan announced on Monday that it completed its acquisition of Hempco Food and Fiber. As part of the deal, Aurora acquired all of Hempco's outstanding shares it didn't already own for approximately 63.4 million Canadian dollars. Hempco will now operate ... | Aurora Cannabis (NYSE: ACB) is expanding its empire. Yet Hempco's primary allure for Aurora is its ability to produce high volumes of low-cost raw hemp, from which cannabidiol (CBD) can be extracted. To seize this lucrative opportunity, Aurora Cannabis has made multiple acquisitions to bolster its hemp production, proc... | Aurora Cannabis (NYSE: ACB) is expanding its empire. The marijuana titan announced on Monday that it completed its acquisition of Hempco Food and Fiber. Its brands include Planet Hemp food products and Praise nutritional supplements for animals. | Aurora Cannabis (NYSE: ACB) is expanding its empire. Aurora Cannabis is strengthening its hemp business with its purchase of Hempco Food and Fiber. The company has combined these businesses into Aurora Hemp, an operating unit with capabilities spanning across the entire hemp and CBD value chain. | Aurora Cannabis (NYSE: ACB) is expanding its empire. Aurora Cannabis is strengthening its hemp business with its purchase of Hempco Food and Fiber. The company has combined these businesses into Aurora Hemp, an operating unit with capabilities spanning across the entire hemp and CBD value chain. |
38215.0 | 2019-08-19 00:00:00 UTC | 7 Marijuana Penny Stocks That I May Buy | ACB | https://www.nasdaq.com/articles/7-marijuana-penny-stocks-that-i-may-buy-2019-08-19 | nan | nan | [Editor’s note: This article was originally published in July 2019. It has since been updated to reflect changes in the market.]
Investing in penny stocks can be appealing to some. And investing in marijuana penny stocks can be even more appealing … if you’re willing to take massive risks. But with great risks comes ev... | As the former CEO of Home Depot (NYSE:), its pretty obvious that he will bring tremendous experience and wisdom to the table. In addition, the company announced that it has also obtained up to $30 million in debt financing and that its stock has been upgraded from the OTCBQ to the OTCQX exchange. This company announced... | Global Hemp Group (GBHPF) Global Hemp Group (OTCMKTS:) develops hemp cultivation for cannabinoid extraction. Global Cannabis Applications Corp (FUAPF) Global Cannabis Applications Corp (OTCMKTS:) is involved in the development of smart phone applications for the cannabis industry. Emerald Health Therapeutics (EMHTF) Em... | 48North Cannabis Corp (NRTH) 48North Cannabis Corp (TSE:) grows and sells medical marijuana. Most of the large cannabis companies such as Aphria (NYSE:) and Aurora Cannabis (NYSE:) grow their cannabis either in indoor growing facilities or greenhouses. Global Cannabis Applications Corp (FUAPF) Global Cannabis Applicati... | The following marijuana penny stocks are offer interesting opportunities for investors willing to take risks on the future of the marijuana industry. This company announced that it has appointed Shay Meir to the position of General Manager, Global Grow Operations. Pure Sunfarms reported all-in growing costs of 65 cents... |
38216.0 | 2019-08-19 00:00:00 UTC | 3 Marijuana Stocks You Should Buy, According to This 124-Year-Old Wall Street Firm | ACB | https://www.nasdaq.com/articles/3-marijuana-stocks-you-should-buy-according-to-this-124-year-old-wall-street-firm-2019-08 | nan | nan | Steadily, the cannabis industry is budding into a big-money business. After generating a little more than $3 billion in worldwide licensed-store sales in 2014, the global pot industry nearly hit $11 billion in sales last year. By 2024, the team of Arcview Market Research and BDS Analytics foresees worldwide weed sales ... | The one pot stock you shouldn't buy... Interestingly, the one marijuana stock Piper Jaffray suggests investors not buy is Aurora Cannabis (NYSE: ACB), which happens to be the most popular weed stock of them all. CV Sciences and its line of PlusCBD Oil products have had a number of big wins this year, with the creme-de-... | The one pot stock you shouldn't buy... Interestingly, the one marijuana stock Piper Jaffray suggests investors not buy is Aurora Cannabis (NYSE: ACB), which happens to be the most popular weed stock of them all. CV Sciences: price target $5, representing 62% upside Considering Piper Jaffray's excitement concerning CBD ... | The one pot stock you shouldn't buy... Interestingly, the one marijuana stock Piper Jaffray suggests investors not buy is Aurora Cannabis (NYSE: ACB), which happens to be the most popular weed stock of them all. While I agree with Lavery that Cronos Group has made a smart choice by focusing on CBD products, and that it... | The one pot stock you shouldn't buy... Interestingly, the one marijuana stock Piper Jaffray suggests investors not buy is Aurora Cannabis (NYSE: ACB), which happens to be the most popular weed stock of them all. CV Sciences: price target $5, representing 62% upside Considering Piper Jaffray's excitement concerning CBD ... |
38217.0 | 2019-08-19 00:00:00 UTC | Hexo Stock Needs Just Two Things to Move Higher | ACB | https://www.nasdaq.com/articles/hexo-stock-needs-just-two-things-to-move-higher-2019-08-19 | nan | nan | Among marijuana equities, Hexo (NYSE:) stock continues to gain increased attention. An alliance with Molson Coors (NYSE:) and a solid base of business in its home province of Quebec have bolstered its business. Also, it looks poised to establish another niche once Canada legalizes cannabis-infused beverages.
Source: Sh... | Source: Shutterstock However, departures in top management and a possible violation of advertising regulations have hurt the company. Strangely, my best returns in trading marijuana stocks came from charting the moves in the beleaguered CannTrust (NYSE:). In a recent article, I told investors to stay away until “it fou... | An alliance with Molson Coors (NYSE:) and a solid base of business in its home province of Quebec have bolstered its business. It could help to make Hexo a leader among cannabis-infused beverages once Canada legalizes those drinks. For next year, analysts estimate that revenues will range between 185.7 million CAD ($13... | Hence, for the Hexo stock price to rise, investors need both a solid floor and a catalyst. Has Hexo Stock Bottomed? To profit from Hexo stock, investors need both a floor and a catalyst. | Among marijuana equities, Hexo (NYSE:) stock continues to gain increased attention. Hence, for the Hexo stock price to rise, investors need both a solid floor and a catalyst. Has Hexo Stock Bottomed? |
38218.0 | 2019-08-19 00:00:00 UTC | How to Position Smartly in ACB Stock | ACB | https://www.nasdaq.com/articles/how-to-position-smartly-in-acb-stock-2019-08-19 | nan | nan | For would-be Aurora Cannabis (NYSE:) bulls intent not to get drawn-in and smoked in a promising secular market trend, the suggestion remains the same. Don’t fix what isn’t broken and stick with the ACB stock price chart rather than outside influences. Let me explain:
It has been a month since cautiously writing about A... | Let me explain: It has been a month since cautiously writing about ACB stock and putting the cannabis producer But similar to an even earlier discussion of Aurora, action was specific to the price chart. Given the decline in ACB stock, doesn’t it now make more sense than ever to embrace Aurora Cannabis as a recognized ... | Don’t fix what isn’t broken and stick with the ACB stock price chart rather than outside influences. It’s good information, but rather than simply get drawn in to Aurora by outside influences, albeit prominent ones, it’s also nice to know the ACB stock price chart also supports this investment proposition in today’s ma... | Let me explain: It has been a month since cautiously writing about ACB stock and putting the cannabis producer But similar to an even earlier discussion of Aurora, action was specific to the price chart. It’s good information, but rather than simply get drawn in to Aurora by outside influences, albeit prominent ones, i... | Thank you, ACB stock. But if the investment in question is ACB stock, you’d be in good company too. Don’t fix what isn’t broken and stick with the ACB stock price chart rather than outside influences. |
38219.0 | 2019-08-18 00:00:00 UTC | Better Buy: Aurora Cannabis vs. Cronos Group | ACB | https://www.nasdaq.com/articles/better-buy%3A-aurora-cannabis-vs.-cronos-group-2019-08-18 | nan | nan | A top analyst recently recommended buying Cronos Group (NASDAQ: CRON). But Piper Jaffray wasn't so bullish on Aurora Cannabis (NYSE: ACB), initiating coverage of the stock with a neutral rating. It wasn't too long ago, though, that analysts were much more positive about Aurora than they were Cronos.
Aurora has outperfo... | But Piper Jaffray wasn't so bullish on Aurora Cannabis (NYSE: ACB), initiating coverage of the stock with a neutral rating. The company recently announced that it's acquiring four operating subsidiaries of Redwood Holding Group, the maker of the Lord Jones line of premium CBD consumer products. Major partnerships Auror... | But Piper Jaffray wasn't so bullish on Aurora Cannabis (NYSE: ACB), initiating coverage of the stock with a neutral rating. A top analyst recently recommended buying Cronos Group (NASDAQ: CRON). Current revenue growth Aurora expects to report quarter-over-quarter net revenue growth of at least 54% when it announces its... | But Piper Jaffray wasn't so bullish on Aurora Cannabis (NYSE: ACB), initiating coverage of the stock with a neutral rating. Production capacity Aurora Cannabis ranks at the top of the industry when it comes to production capacity. Aurora is also developing cannabis-infused beverages, but Chief Corporate Officer Cam Bat... | But Piper Jaffray wasn't so bullish on Aurora Cannabis (NYSE: ACB), initiating coverage of the stock with a neutral rating. Aurora isn't there yet, though: It produced around 30,000 kilograms of cannabis for sale in its latest quarter. Canadian market position As you might expect, Aurora has a much larger market share ... |
38220.0 | 2019-08-16 00:00:00 UTC | After Sliding into Mediocrity, Tilray Stock May Be a Buy on This Dip | ACB | https://www.nasdaq.com/articles/after-sliding-into-mediocrity-tilray-stock-may-be-a-buy-on-this-dip-2019-08-16 | nan | nan | A slew of recent earnings reports across the cannabis sector, from Canopy Growth (NYSE:) to Tilray (NASDAQ:), have confirmed an overwhelmingly bearish reality for cannabis companies: these companies are going to lose hundreds of millions, if not billions, of dollars before they ever net a profit. Tilray stock still is ... | When doing so, the names to buy are sector giants CGC and ACB, and also rising cannabis star TLRY. As of this writing, Luke Lango was long CGC, ACB, and TLRY. A slew of recent earnings reports across the cannabis sector, from Canopy Growth (NYSE:) to Tilray (NASDAQ:), have confirmed an overwhelmingly bearish reality fo... | When doing so, the names to buy are sector giants CGC and ACB, and also rising cannabis star TLRY. As of this writing, Luke Lango was long CGC, ACB, and TLRY. A slew of recent earnings reports across the cannabis sector, from Canopy Growth (NYSE:) to Tilray (NASDAQ:), have confirmed an overwhelmingly bearish reality fo... | When doing so, the names to buy are sector giants CGC and ACB, and also rising cannabis star TLRY. As of this writing, Luke Lango was long CGC, ACB, and TLRY. A slew of recent earnings reports across the cannabis sector, from Canopy Growth (NYSE:) to Tilray (NASDAQ:), have confirmed an overwhelmingly bearish reality fo... | When doing so, the names to buy are sector giants CGC and ACB, and also rising cannabis star TLRY. As of this writing, Luke Lango was long CGC, ACB, and TLRY. But, that’s just what happens when you are less than a year into a new growth market. |
38221.0 | 2019-08-15 00:00:00 UTC | Aurora Cannabis Expands Credit Facility by 80% | ACB | https://www.nasdaq.com/articles/aurora-cannabis-expands-credit-facility-by-80-2019-08-15 | nan | nan | Aurora Cannabis (NYSE: ACB) has increased its financial leverage. The company announced on Thursday that it has managed to nearly double an existing credit facility.
The company says that the syndicate behind the facility has agreed to expand it to roughly 360 million Canadian dollars from the previous level of CA$200 ... | Aurora Cannabis (NYSE: ACB) has increased its financial leverage. Access to this non-dilutive capital is a core funding source the Company intends to utilize as it further executes on its strategic growth initiatives. Capital is particularly valuable for marijuana companies at the moment because many are eager to build... | Aurora Cannabis (NYSE: ACB) has increased its financial leverage. Aurora did quote its CFO, Glen Ibbott, as saying: The upsizing of our credit facility to approximately CA$360 million and the broadening of the lending syndicate to include additional Schedule 1 Canadian Banks is further recognition that our best-in-clas... | Aurora Cannabis (NYSE: ACB) has increased its financial leverage. Aurora did quote its CFO, Glen Ibbott, as saying: The upsizing of our credit facility to approximately CA$360 million and the broadening of the lending syndicate to include additional Schedule 1 Canadian Banks is further recognition that our best-in-clas... | Aurora Cannabis (NYSE: ACB) has increased its financial leverage. Aurora did not specify other terms for the new funding. 10 stocks we like better than Aurora Cannabis Inc. |
38222.0 | 2019-08-15 00:00:00 UTC | Aurora Cannabis Stock: 3 Reasons Not to Buy Into the Hype | ACB | https://www.nasdaq.com/articles/aurora-cannabis-stock%3A-3-reasons-not-to-buy-into-the-hype-2019-08-15 | nan | nan | Aurora Cannabis (NASDAQ:) is one of the most popular cannabis stocks on the market right now. Analysts are pretty evenly split when it comes to the stock. About half are in favor of ACB stock while the rest are more hesitant to jump on board.
This week, fell after a Piper Jaffray’s analyst shared a more bearish view o... | About half are in favor of ACB stock while the rest are more hesitant to jump on board. , I wrote that ACB stock has potential but is a risky stock to invest in due to a number of headwinds. Of course, this doesn’t directly involve ACB stock. | About half are in favor of ACB stock while the rest are more hesitant to jump on board. , I wrote that ACB stock has potential but is a risky stock to invest in due to a number of headwinds. Of course, this doesn’t directly involve ACB stock. | About half are in favor of ACB stock while the rest are more hesitant to jump on board. , I wrote that ACB stock has potential but is a risky stock to invest in due to a number of headwinds. Of course, this doesn’t directly involve ACB stock. | About half are in favor of ACB stock while the rest are more hesitant to jump on board. , I wrote that ACB stock has potential but is a risky stock to invest in due to a number of headwinds. Of course, this doesn’t directly involve ACB stock. |
38223.0 | 2019-08-15 00:00:00 UTC | The 4-Letter Word Cannabis Investors Need to Know | ACB | https://www.nasdaq.com/articles/the-4-letter-word-cannabis-investors-need-to-know-2019-08-15 | nan | nan | Over the next decade, the global marijuana industry is expected to deliver once-in-a-generation-type growth potential. Following a year that saw worldwide licensed-store sales climb to $10.9 billion, projections from Arcview Market Research and BDS Analytics suggest that global weed sales could top $40 billion by 2024,... | It's time to temper your near-term expectations Take the most popular marijuana stock in the world, Aurora Cannabis (NYSE: ACB), as the perfect relatable example. Whether we're talking about the rise of the internet, business-to-business commerce, decoding the human genome, 3D printing, blockchain technology, or a host... | It's time to temper your near-term expectations Take the most popular marijuana stock in the world, Aurora Cannabis (NYSE: ACB), as the perfect relatable example. Meanwhile, in the U.S., much of the blame for tempered sales results (ahem, California) rests with high tax rates on legalized cannabis. The aggregate tax ra... | It's time to temper your near-term expectations Take the most popular marijuana stock in the world, Aurora Cannabis (NYSE: ACB), as the perfect relatable example. Following a year that saw worldwide licensed-store sales climb to $10.9 billion, projections from Arcview Market Research and BDS Analytics suggest that glob... | It's time to temper your near-term expectations Take the most popular marijuana stock in the world, Aurora Cannabis (NYSE: ACB), as the perfect relatable example. The four-letter word pot stock investors need to know But success as a cannabis stock investor is far from a given. But the thing about next-big-thing invest... |
38224.0 | 2019-08-15 00:00:00 UTC | Forget Aurora Cannabis, a Top Analyst Says Buy These 5 Pot Stocks Instead | ACB | https://www.nasdaq.com/articles/forget-aurora-cannabis-a-top-analyst-says-buy-these-5-pot-stocks-instead-2019-08-15 | nan | nan | Not long ago, Aurora Cannabis (NYSE: ACB) ranked as the darling of Wall Street analysts. But analysts can be quite fickle. Bank of America Merrill Lynch's Christopher Carey downgraded Aurora from buy to neutral in July. Now another top analyst has expressed a lack of confidence in Aurora's prospects.
Earlier this week,... | Not long ago, Aurora Cannabis (NYSE: ACB) ranked as the darling of Wall Street analysts. Piper Jaffray also thinks that Altria can help open doors to retailers in the U.S. for CBD products and brings plenty of regulatory and vape expertise to the table. I like Piper Jaffray's buy recommendations for Charlotte's Web, CV... | Not long ago, Aurora Cannabis (NYSE: ACB) ranked as the darling of Wall Street analysts. All of the other cannabis stocks with buy recommendations from Piper Jaffray are based in the U.S. Two of them are hemp CBD companies -- Charlotte's Web Holdings (OTC: CWBHF) and CV Sciences (OTC: CVSI). The remaining two stocks am... | Not long ago, Aurora Cannabis (NYSE: ACB) ranked as the darling of Wall Street analysts. Although Piper Jaffray doesn't recommend buying Aurora Cannabis, there are five pot stocks the firm does like right now. Piper Jaffray's high five So which pot stocks does Piper Jaffray prefer over Aurora Cannabis? | Not long ago, Aurora Cannabis (NYSE: ACB) ranked as the darling of Wall Street analysts. Although Piper Jaffray doesn't recommend buying Aurora Cannabis, there are five pot stocks the firm does like right now. Down on Aurora Why doesn't Piper Jaffray like Aurora? |
38225.0 | 2019-08-14 00:00:00 UTC | Canopy Needs Its Earnings to Answer These Key Questions | ACB | https://www.nasdaq.com/articles/canopy-needs-its-earnings-to-answer-these-key-questions-2019-08-14 | nan | nan | The cannabis sector has been struggling — that’s no secret to those that follow along with the space. But with key companies like Tilray (NASDAQ:) and Canopy Growth (NYSE:) reporting earnings this week, even more attention is being thrust onto the group.
Source: Shutterstock
We for TLRY stock ahead of earnings — some u... | But with key companies like Tilray (NASDAQ:) and Canopy Growth (NYSE:) reporting earnings this week, even more attention is being thrust onto the group. Because of the regulatory hurdles, speculative nature of M&A, incredible growth rates and high valuations, cannabis stocks are volatile bunch. Shares were setting up i... | But with key companies like Tilray (NASDAQ:) and Canopy Growth (NYSE:) reporting earnings this week, even more attention is being thrust onto the group. Source: Shutterstock We for TLRY stock ahead of earnings — some upside targets should the post-earnings reaction be positive and some downside targets if the stock is ... | Source: Shutterstock We for TLRY stock ahead of earnings — some upside targets should the post-earnings reaction be positive and some downside targets if the stock is under pressure. Trading CGC Stock Just over a month ago, we flagged the bearish price action in Canopy Growth stock price. Canopy Growth Stock Earnings P... | Now back down toward $32, Canopy Growth stock is near a key level. On the upside, CGC stock needs to clear the 20-day moving average and downtrend resistance (blue line). Canopy Growth Stock Earnings Preview Without question, CGC is considered one of the “blue chips” of cannabis stocks. |
38226.0 | 2019-08-14 00:00:00 UTC | Is Aurora Cannabis Stock Worth Buying? | ACB | https://www.nasdaq.com/articles/is-aurora-cannabis-stock-worth-buying-2019-08-14 | nan | nan | [Editor’s Note: This article was updated on Aug. 15 to correct the location of Lift & Co.]
Piper Jaffray analyst Michael Lavery initiated coverage of Aurora Cannabis (NYSE:) stock with a “neutral” rating on Aug. 13. At the same time, the analyst gave a number of its Canadian competitors, including Cronos Group (NAS... | The Bottom Line on ACB Stock ACB’s Germany, Denmark, and Latin American operations enable it to produce a significant amount of cannabis and hemp in overseas countries whose populations total more than people. [Editor’s Note: This article was updated on Aug. 15 to correct the location of Lift & Co.] Piper Jaffray analy... | The Bottom Line on ACB Stock ACB’s Germany, Denmark, and Latin American operations enable it to produce a significant amount of cannabis and hemp in overseas countries whose populations total more than people. InvestorPlace columnist Luke Lango, in May that the market valued Aurora Cannabis at less than $1 million per ... | The Bottom Line on ACB Stock ACB’s Germany, Denmark, and Latin American operations enable it to produce a significant amount of cannabis and hemp in overseas countries whose populations total more than people. Profitability May Be Elusive for Aurora Cannabis Most of the major cannabis companies aren’t profitable. Inves... | The Bottom Line on ACB Stock ACB’s Germany, Denmark, and Latin American operations enable it to produce a significant amount of cannabis and hemp in overseas countries whose populations total more than people. Lavery’s against Aurora Cannabis stock has to do with its rich valuation combined with the fact that the compa... |
38227.0 | 2019-08-14 00:00:00 UTC | After Earnings, TLRY Stock Remains a Strategy Play | ACB | https://www.nasdaq.com/articles/after-earnings-tlry-stock-remains-a-strategy-play-2019-08-14 | nan | nan | It seems like Tilray (NASDAQ:) has returned to normal. Heading into second-quarter earnings on Tuesday, Tilray news had been relatively quiet. Tilray stock had traded sideways.
Source: Shutterstock
Put another way, there hasn’t been much in the way of fireworks. But that’s not necessarily a bad thing. The first on the ... | Tilray stock actually has held up reasonably well in a market that has been unkind to most pot plays, with leaders like Canopy Growth (NYSE:) and Cronos (NASDAQ:) well off their highs. The fact that Aphria (NYSE:) posted a blowout quarter last month, and guided for positive Adjusted EBITDA, may be a factor. At the leas... | The fact that Aphria (NYSE:) posted a blowout quarter last month, and guided for positive Adjusted EBITDA, may be a factor. At the least, it’s a strategy based on the thesis that those companies spending hundreds of millions of dollars to build production — and drive near-term revenue — are making a mistake. In additio... | Some disappointing Tilray news has changed that somewhat, as TLRY slid more than 10% in after-hours trading following earnings on Tuesday afternoon. Tilray News Looks OK Tilray seems to have been hit by a somewhat odd fact of cannabis investing at the moment: investors over revenue. Vertically integrated producers like... | Tilray News Looks OK Tilray seems to have been hit by a somewhat odd fact of cannabis investing at the moment: investors over revenue. The fact that Aphria (NYSE:) posted a blowout quarter last month, and guided for positive Adjusted EBITDA, may be a factor. That said, Tilray did post a big revenue beat relative to exp... |
38228.0 | 2019-08-14 00:00:00 UTC | 2 Pot Stocks in Big Danger of a Writedown | ACB | https://www.nasdaq.com/articles/2-pot-stocks-in-big-danger-of-a-writedown-2019-08-14 | nan | nan | For years, the marijuana industry has been budding before Wall Street's and investors' eyes. After growing to $10.9 billion in legal licensed-store sales in 2018, the newest report, "State of the Legal Cannabis Markets," from Arcview Market Research and BDS Analytics calls for a compound annual global growth rate of be... | As of Aurora Cannabis' (NYSE: ACB) fiscal third-quarter operating results, the company that had made 15 acquisitions since August 2016 was lugging around 3.18 billion Canadian dollars in goodwill (about $2.39 billion), which compares to the company's total assets of CA$5.55 billion. This type of growth opportunity simp... | As of Aurora Cannabis' (NYSE: ACB) fiscal third-quarter operating results, the company that had made 15 acquisitions since August 2016 was lugging around 3.18 billion Canadian dollars in goodwill (about $2.39 billion), which compares to the company's total assets of CA$5.55 billion. As of March 31, 2019, Aurora recogni... | As of Aurora Cannabis' (NYSE: ACB) fiscal third-quarter operating results, the company that had made 15 acquisitions since August 2016 was lugging around 3.18 billion Canadian dollars in goodwill (about $2.39 billion), which compares to the company's total assets of CA$5.55 billion. There are, however, two pot stocks w... | As of Aurora Cannabis' (NYSE: ACB) fiscal third-quarter operating results, the company that had made 15 acquisitions since August 2016 was lugging around 3.18 billion Canadian dollars in goodwill (about $2.39 billion), which compares to the company's total assets of CA$5.55 billion. This premium is often recognized on ... |
38229.0 | 2019-08-13 00:00:00 UTC | Canopy Growth is Pushing CGC Stock to an Inflection Point | ACB | https://www.nasdaq.com/articles/canopy-growth-is-pushing-cgc-stock-to-an-inflection-point-2019-08-13 | nan | nan | It’s an admittedly tired trope regarding Canopy Growth (NYSE:). Many owners of CGC stock have largely learned to ignore the rhetoric, recognizing it takes money now to make money later. The company’s heavy spending is setting the stage for a bright future rather than an impressive present.
Source: Shutterstock
What mos... | Source: Shutterstock What most Canopy Growth stock owners may not fully appreciate is the extent to which the company is — figuratively and somewhat literally — betting the farm on a future that may or may not materialize. Canopy Growth Stock as Cheap Currency Bloomberg Intelligence analyst Kenneth Shea rang the alarm ... | The move gave roughly 40% of the cannabis company to Constellation, and gave Canopy Growth a much-needed cash infusion. In its fourth and final quarter of the year alone, stock-based compensation cost Canopy Growth $93.2 million, $74.7 million of which was effectively part of employee paychecks; the other $18.5 million... | Source: Shutterstock What most Canopy Growth stock owners may not fully appreciate is the extent to which the company is — figuratively and somewhat literally — betting the farm on a future that may or may not materialize. Canopy Growth Stock as Cheap Currency Bloomberg Intelligence analyst Kenneth Shea rang the alarm ... | Canopy Growth’s balance sheet consisted of $2.5 billion in cash, and a little more than $2 billion worth of marketable securities. Shea specifically names Aphria, Aurora Cannabis (NYSE:) and — you guessed it — Canopy Growth as names particularly vulnerable to writedowns. For the quarter ending in December, compensation... |
38230.0 | 2019-08-13 00:00:00 UTC | 10 Figures in Canopy Growth's First-Quarter Report You'll Want to Know | ACB | https://www.nasdaq.com/articles/10-figures-in-canopy-growths-first-quarter-report-youll-want-to-know-2019-08-13 | nan | nan | The big day is nearly here, at least for cannabis investors. On Thursday morning, Aug. 15, Canopy Growth (NYSE: CGC), the largest marijuana stock in the world by market cap, will report its first-quarter operating results for fiscal 2020.
According to the 10 Wall Street analysts currently offering quarterly estimates, ... | That's in stark contrast to Aurora Cannabis (NYSE: ACB), which recently guided to sequential quarterly sales growth of 59% at the midpoint. On Thursday morning, Aug. 15, Canopy Growth (NYSE: CGC), the largest marijuana stock in the world by market cap, will report its first-quarter operating results for fiscal 2020. As... | That's in stark contrast to Aurora Cannabis (NYSE: ACB), which recently guided to sequential quarterly sales growth of 59% at the midpoint. With net revenue of CA$94.1 million in the fourth quarter, the current gross revenue estimate of CA$109.2 million on the Street suggests virtually flat quarter-over-quarter sales. ... | That's in stark contrast to Aurora Cannabis (NYSE: ACB), which recently guided to sequential quarterly sales growth of 59% at the midpoint. According to the 10 Wall Street analysts currently offering quarterly estimates, Canopy's consensus is for 109.2 million Canadian dollars in gross sales (ranging from a low of CA$9... | That's in stark contrast to Aurora Cannabis (NYSE: ACB), which recently guided to sequential quarterly sales growth of 59% at the midpoint. Still, it'd be surprising if we didn't see some improvement in international sales figures from the sequential fourth quarter. Operating loss It's pretty much no secret that Canopy... |
38231.0 | 2019-08-12 00:00:00 UTC | A $3 Opportunity in Aurora Cannabis Stock | ACB | https://www.nasdaq.com/articles/a-%243-opportunity-in-aurora-cannabis-stock-2019-08-12 | nan | nan | There could be a $3 rally brewing in Aurora Cannabis (NYSE:) soon. The setup for this is almost perfect but it will take intestinal fortitude to hold ACB stock during this uncertainty on Wall Street.
This morning we are seeing video of that could make the problems with China more acute. So the short term prognosis for ... | So the buyers now have more conviction than they did just a few months ago, thereby making the investors now stronger hands holding ACB stock. The setup for this is almost perfect but it will take intestinal fortitude to hold ACB stock during this uncertainty on Wall Street. But with the advent of other distractions li... | So if we assume now that the stock markets in general are not collapsing, then it is safe to also assume that ACB stock buyers will make another effort to push prices towards the highs once more. The setup for this is almost perfect but it will take intestinal fortitude to hold ACB stock during this uncertainty on Wall... | But with the advent of other distractions like IPOs, the novelty of cannabis stocks waned including ACB stock. So if we assume now that the stock markets in general are not collapsing, then it is safe to also assume that ACB stock buyers will make another effort to push prices towards the highs once more. The setup for... | But in March of this year, ACB stock topped out at $10 per share. The setup for this is almost perfect but it will take intestinal fortitude to hold ACB stock during this uncertainty on Wall Street. But with the advent of other distractions like IPOs, the novelty of cannabis stocks waned including ACB stock. |
38232.0 | 2019-08-12 00:00:00 UTC | 3 Pot Stocks That Can Outsell Aurora Cannabis in 2020 | ACB | https://www.nasdaq.com/articles/3-pot-stocks-that-can-outsell-aurora-cannabis-in-2020-2019-08-12 | nan | nan | As you're probably aware, the marijuana industry is a big-money business. Even though more money is currently being spent in the black market at the moment, the idea is that as more countries push to legalize cannabis, consumers will steadily move into legal channels. In a decade's time, we could be looking at aglobal ... | Investors can't get enough of Aurora Cannabis Potentially heading the legalization charge is the most popular pot stock in the world, Aurora Cannabis (NYSE: ACB). It has 56 retail store licenses, will operate in just under a dozen states, and is poised to benefit from Illinois legalizing recreational weed and commencin... | Investors can't get enough of Aurora Cannabis Potentially heading the legalization charge is the most popular pot stock in the world, Aurora Cannabis (NYSE: ACB). Already producing at an annual run-rate of 150,000 kilos, the company has forecast a push to at least 625,000 kilos of yearly run-rate output by the time its... | Investors can't get enough of Aurora Cannabis Potentially heading the legalization charge is the most popular pot stock in the world, Aurora Cannabis (NYSE: ACB). Cresco Labs: $715 million Yet another vertically integrated dispensary operator that could blow Aurora out of the water in terms of 2020 full-year sales is C... | Investors can't get enough of Aurora Cannabis Potentially heading the legalization charge is the most popular pot stock in the world, Aurora Cannabis (NYSE: ACB). Cresco Labs: $715 million Yet another vertically integrated dispensary operator that could blow Aurora out of the water in terms of 2020 full-year sales is C... |
38233.0 | 2019-08-12 00:00:00 UTC | 10 Medical Marijuana Stocks to Cure Your Portfolio | ACB | https://www.nasdaq.com/articles/10-medical-marijuana-stocks-to-cure-your-portfolio-2019-08-12 | nan | nan | Editor’s note: This story was previously published in April 2019. It has since been updated and republished.
Invariably, no other investment class generates as much interest and controversy as marijuana stocks. Within a generation, toward legalization shifted dramatically from strongly opposed to mostly supportive. Thi... | Aurora Cannabis (ACB) I’ve spent a lot of time discussing Aurora Cannabis (NYSE:), and I don’t mean to keep double-dipping into this company. Still, I keep going back for a reason: ACB stock is an excellent play within the medical-marijuana market. Furthermore, ACB stock is a strong performer. | Aurora Cannabis (ACB) I’ve spent a lot of time discussing Aurora Cannabis (NYSE:), and I don’t mean to keep double-dipping into this company. Still, I keep going back for a reason: ACB stock is an excellent play within the medical-marijuana market. Furthermore, ACB stock is a strong performer. | Aurora Cannabis (ACB) I’ve spent a lot of time discussing Aurora Cannabis (NYSE:), and I don’t mean to keep double-dipping into this company. Still, I keep going back for a reason: ACB stock is an excellent play within the medical-marijuana market. Furthermore, ACB stock is a strong performer. | Aurora Cannabis (ACB) I’ve spent a lot of time discussing Aurora Cannabis (NYSE:), and I don’t mean to keep double-dipping into this company. Still, I keep going back for a reason: ACB stock is an excellent play within the medical-marijuana market. Furthermore, ACB stock is a strong performer. |
38234.0 | 2019-08-11 00:00:00 UTC | Why Aurora Cannabis, Cronos Group, and Canopy Growth Plunged in July | ACB | https://www.nasdaq.com/articles/why-aurora-cannabis-cronos-group-and-canopy-growth-plunged-in-july-2019-08-12 | nan | nan | What happened
Shares of Aurora Cannabis (NYSE: ACB), Cronos Group (NASDAQ: CRON), and Canopy Growth (NYSE: CGC) all fell more than 13% last month, according to data provided by S&P Global Market Intelligence, after a regulatory scandal spooked investors.
So what
Cannabis stocks were rocked by the news that Canadian pro... | What happened Shares of Aurora Cannabis (NYSE: ACB), Cronos Group (NASDAQ: CRON), and Canopy Growth (NYSE: CGC) all fell more than 13% last month, according to data provided by S&P Global Market Intelligence, after a regulatory scandal spooked investors. While it's unlikely that Aurora, Cronos, or Canopy Growth would m... | What happened Shares of Aurora Cannabis (NYSE: ACB), Cronos Group (NASDAQ: CRON), and Canopy Growth (NYSE: CGC) all fell more than 13% last month, according to data provided by S&P Global Market Intelligence, after a regulatory scandal spooked investors. So what Cannabis stocks were rocked by the news that Canadian pro... | What happened Shares of Aurora Cannabis (NYSE: ACB), Cronos Group (NASDAQ: CRON), and Canopy Growth (NYSE: CGC) all fell more than 13% last month, according to data provided by S&P Global Market Intelligence, after a regulatory scandal spooked investors. So what Cannabis stocks were rocked by the news that Canadian pro... | What happened Shares of Aurora Cannabis (NYSE: ACB), Cronos Group (NASDAQ: CRON), and Canopy Growth (NYSE: CGC) all fell more than 13% last month, according to data provided by S&P Global Market Intelligence, after a regulatory scandal spooked investors. Aurora is the leading producer by peak production capacity, while... |
38235.0 | 2019-08-08 00:00:00 UTC | Cronos Group's Q2 Trounces Estimates | ACB | https://www.nasdaq.com/articles/cronos-groups-q2-trounces-estimates-2019-08-08 | nan | nan | Cronos Group (NASDAQ: CRON) is the latest marijuana stock to post substantially better-than-expected financials this earnings season. The company released results for its fiscal second quarter of 2019 today, and they were surprisingly robust.
For the quarter, Cronos booked net revenue of 10.2 million Canadian dollars, ... | For example, Aurora Cannabis (NYSE: ACB), which just unveiled preliminary figures for its fiscal Q4, expects to post a more-than-fivefold increase in revenue. Cronos Group (NASDAQ: CRON) is the latest marijuana stock to post substantially better-than-expected financials this earnings season. Cronos' results come close ... | For example, Aurora Cannabis (NYSE: ACB), which just unveiled preliminary figures for its fiscal Q4, expects to post a more-than-fivefold increase in revenue. For the quarter, Cronos booked net revenue of 10.2 million Canadian dollars, which was more than three times higher than the Q2 2018 figure. That CA$10.2 million... | For example, Aurora Cannabis (NYSE: ACB), which just unveiled preliminary figures for its fiscal Q4, expects to post a more-than-fivefold increase in revenue. That CA$10.2 million was significantly higher than the CA$7.3 million expected by analysts. Cronos' results come close on the heels of big revenue gains for othe... | For example, Aurora Cannabis (NYSE: ACB), which just unveiled preliminary figures for its fiscal Q4, expects to post a more-than-fivefold increase in revenue. For the quarter, Cronos booked net revenue of 10.2 million Canadian dollars, which was more than three times higher than the Q2 2018 figure. That CA$10.2 million... |
38236.0 | 2019-08-08 00:00:00 UTC | The 5 Biggest Marijuana Deals in History | ACB | https://www.nasdaq.com/articles/the-5-biggest-marijuana-deals-in-history-2019-08-08 | nan | nan | If there's one thing we've learned about the marijuana industry over the past couple of years, it's that it's dynamic. With growth prospects for the industry skyrocketing, cannabis stocks have continued to evolve their businesses to take advantage of the changing marijuana landscape.
One of the many ways we've seen thi... | Aurora Cannabis acquires MedReleaf for $2 billion Though it may seem like eons ago, the largest completed acquisition in the marijuana space is Aurora Cannabis' (NYSE: ACB) all-stock purchase of Ontario-based MedReleaf in July 2018 for $2 billion (in today's dollars, when converted from Canadian dollars). With plenty o... | Aurora Cannabis acquires MedReleaf for $2 billion Though it may seem like eons ago, the largest completed acquisition in the marijuana space is Aurora Cannabis' (NYSE: ACB) all-stock purchase of Ontario-based MedReleaf in July 2018 for $2 billion (in today's dollars, when converted from Canadian dollars). In mid-April,... | Aurora Cannabis acquires MedReleaf for $2 billion Though it may seem like eons ago, the largest completed acquisition in the marijuana space is Aurora Cannabis' (NYSE: ACB) all-stock purchase of Ontario-based MedReleaf in July 2018 for $2 billion (in today's dollars, when converted from Canadian dollars). Constellation... | Aurora Cannabis acquires MedReleaf for $2 billion Though it may seem like eons ago, the largest completed acquisition in the marijuana space is Aurora Cannabis' (NYSE: ACB) all-stock purchase of Ontario-based MedReleaf in July 2018 for $2 billion (in today's dollars, when converted from Canadian dollars). In October 20... |
38237.0 | 2019-08-07 00:00:00 UTC | Will Earnings Light Up Canopy Growth Stock? | ACB | https://www.nasdaq.com/articles/will-earnings-light-up-canopy-growth-stock-2019-08-07 | nan | nan | Patience can go a long way for investors. Just look at Canopy Growth (NYSE:) stock. Not long ago, investors were frenetically buying up CGC stock.
Source: Shutterstock
Yet lately things have not gone so well. Since mid-April, Canopy Growth stock price has gone from $50 to $32.
When it comes to high-flying stocks, inves... | For the most part, CGC has a pretty good chance of beating the average estimates, mainly because its previous quarterly results, which were disappointing, have tempered expectations. Continuing problems with CGC’s supply chain and black market activities weighed on its Canadian recreational sales. While Linton, its fir... | Just look at Canopy Growth (NYSE:) stock. CGC also reported a massive net loss of C$323.4 million, or 98 cents per share of Canopy Growth stock. Things got so bad for CGC that Constellation Brands (NYSE:) CEO, William Newlands, whose company invested $4 billion in CGC, said he was “not pleased with Canopy’s recent rep... | CGC also reported a massive net loss of C$323.4 million, or 98 cents per share of Canopy Growth stock. Things got so bad for CGC that Constellation Brands (NYSE:) CEO, William Newlands, whose company invested $4 billion in CGC, said he was “not pleased with Canopy’s recent reported year end results.” In the wake of CG... | CGC also reported a massive net loss of C$323.4 million, or 98 cents per share of Canopy Growth stock. Things got so bad for CGC that Constellation Brands (NYSE:) CEO, William Newlands, whose company invested $4 billion in CGC, said he was “not pleased with Canopy’s recent reported year end results.” In the wake of CG... |
38238.0 | 2019-08-07 00:00:00 UTC | Buy Canopy Growth Stock Now, Before the Second-Half Bounce | ACB | https://www.nasdaq.com/articles/buy-canopy-growth-stock-now-before-the-second-half-bounce-2019-08-07 | nan | nan | Marijuana stocks have been hit hard over the past few months, as investors have apparently lost confidence in the sector amid disappointing sales trends in Canada, a lack of legislative progress in the U.S., and huge competitive pressures which have eroded margins and made sustainable profitability seem like a long sho... | As of this writing, Luke Lango was long CGC and ACB. Marijuana stocks have been hit hard over the past few months, as investors have apparently lost confidence in the sector amid disappointing sales trends in Canada, a lack of legislative progress in the U.S., and huge competitive pressures which have eroded margins an... | As of this writing, Luke Lango was long CGC and ACB. But in the long run, the huge rallies of the marijuana stocks will materially outweigh their gigantic drops, and Canopy Growth stock price will jump meaningfully in the next five to ten years. Right now, it looks like CGC stock is positioned to go from “huge drop mo... | As of this writing, Luke Lango was long CGC and ACB. But now is the time to buy the dip of CGC stock because all is not lost In the big picture, CGC stock – along with all other marijuana stocks – will be very volatile for a long time. Right now, it looks like CGC stock is positioned to go from “huge drop mode” to “tre... | As of this writing, Luke Lango was long CGC and ACB. But now is the time to buy the dip of CGC stock because all is not lost In the big picture, CGC stock – along with all other marijuana stocks – will be very volatile for a long time. Overall, then, it appears the fundamentals underlying the Canadian cannabis market a... |
38239.0 | 2019-08-07 00:00:00 UTC | Should You Buy Hexo Stock? 3 Pros, 3 Cons | ACB | https://www.nasdaq.com/articles/should-you-buy-hexo-stock-3-pros-3-cons-2019-08-07 | nan | nan | The marijuana market has created an appealing opportunity for risk-tolerant investors who are willing to wait out the near-term turbulence. However, while deciding to invest in the cannabis boom might seem like a no-brainer, choosing a winner in the space takes a bit more analysis. Recently, Canadian marijuana firm Hex... | The firm partnered with Molson Coors Brewing (NYSE:), which looks likely to provide a large international growth runway as the marijuana market around the world develops. Pro: It’s on Sale Another reason investors might be interested in considering the Canadian marijuana company is then fact that Hexo’s stock price is ... | Recently, Canadian marijuana firm Hexo Corp (NYSE:) has gained a lot of attention and made many traders’ short list. Pro: Hexo Stock Is Seeing Market Share Growth Right now, Hexo controls roughly 30% of Quebec’s marijuana market. Pro: Analyst Recommendations Of the 14 analysts who cover Hexo stock, 10 recommend buying ... | Pro: Hexo Stock Is Seeing Market Share Growth Right now, Hexo controls roughly 30% of Quebec’s marijuana market. Plus, Hexo CEO Sebastien St-Louis has been open about his plans to partner with big names across a variety of industries in order to drive growth for HEXO stock in the years ahead. Hexo stock only recently g... | Pro: Hexo Stock Is Seeing Market Share Growth Right now, Hexo controls roughly 30% of Quebec’s marijuana market. Part of the reason for HEXO’s elevated multiples is the fact that the industry has a lot of potential growth on the horizon, but that doesn’t take away the risk that investors are taking on by buying in an a... |
38240.0 | 2019-08-07 00:00:00 UTC | 4 CBD Stocks to Buy for Mainstream Marijuana Profits | ACB | https://www.nasdaq.com/articles/4-cbd-stocks-to-buy-for-mainstream-marijuana-profits-2019-08-07 | nan | nan | [Editor’s note: This story was previously published in March 2019. It has since been updated and republished.]
Traffic stats don’t lie: among investment categories, few have the draw of legal marijuana. And within this broad segment, companies specializing in cannabidiol, or CBD, have generated significant buzz. But wh... | Aurora Cannabis (ACB) Source: Shutterstock On paper, Aurora Cannabis (NYSE:) is a winner. Year-to-date, stakeholders of ACB stock are sitting on a 29% profit. Since the end of March, ACB stock has shed an alarming 30%. | Aurora Cannabis (ACB) Source: Shutterstock On paper, Aurora Cannabis (NYSE:) is a winner. Year-to-date, stakeholders of ACB stock are sitting on a 29% profit. Since the end of March, ACB stock has shed an alarming 30%. | Aurora Cannabis (ACB) Source: Shutterstock On paper, Aurora Cannabis (NYSE:) is a winner. Year-to-date, stakeholders of ACB stock are sitting on a 29% profit. Since the end of March, ACB stock has shed an alarming 30%. | Aurora Cannabis (ACB) Source: Shutterstock On paper, Aurora Cannabis (NYSE:) is a winner. Year-to-date, stakeholders of ACB stock are sitting on a 29% profit. Since the end of March, ACB stock has shed an alarming 30%. |
38241.0 | 2019-08-07 00:00:00 UTC | 3 Canadian Cannabis Stocks With the Best U.S. Strategies | ACB | https://www.nasdaq.com/articles/3-canadian-cannabis-stocks-with-the-best-u.s.-strategies-2019-08-07 | nan | nan | It's not by accident that the biggest cannabis stocks belong to companies based in Canada. After all, Canada was the first major economic power to legalize adult-use recreational cannabis after already building a thriving medical cannabis market.
But it's also no secret that the U.S. is by far the biggest cannabis mark... | Aurora Cannabis (NYSE: ACB) has been clear that it intends to find one or more major partners from outside the cannabis industry as part of its strategy to enter the U.S. market. With big U.S.-based partner Constellation Brands at its side and some bold moves so far, Canopy appears to be in a strong position to establi... | Aurora Cannabis (NYSE: ACB) has been clear that it intends to find one or more major partners from outside the cannabis industry as part of its strategy to enter the U.S. market. Canopy Growth Canopy Growth (NYSE: CGC) ranks as the biggest cannabis stock by market cap. Redwood markets the Lord Jones lineup of hemp CBD ... | Aurora Cannabis (NYSE: ACB) has been clear that it intends to find one or more major partners from outside the cannabis industry as part of its strategy to enter the U.S. market. For Canadian cannabis companies to achieve the growth that they and investors want, they must enter the U.S. market sooner or later. Canopy G... | Aurora Cannabis (NYSE: ACB) has been clear that it intends to find one or more major partners from outside the cannabis industry as part of its strategy to enter the U.S. market. Here are the three Canadian cannabis stocks that appear to be in the best position to win in the U.S. But Canopy's biggest deal came in April... |
38242.0 | 2019-08-07 00:00:00 UTC | Why CGC Stock Needs a Huge Earnings Report | ACB | https://www.nasdaq.com/articles/why-cgc-stock-needs-a-huge-earnings-report-2019-08-07 | nan | nan | The news just keeps getting worse for Canopy Growth (NYSE:). The Canopy Growth stock price has fallen by over one-third just since the beginning of May. And the issues go beyond CGC stock price.
Source: Shutterstock
Fiscal Q4 earnings in June disappointed, with investors . The company is fighting with majority sharehol... | And investors might do well to see that report come in — and play the ensuing bounce — rather than betting on a company that, right now, doesn’t look like it’s headed in the right direction. Next week’s earnings, due on Wednesday afternoon, seem like the best potential catalyst Canopy Growth has. Aphria posted better-t... | At $32, investors now can buy CGC stock at roughly the same effective price paid by Constellation Brands. Why Earnings Matter for the Canopy Growth Stock Price The trajectory of CGC stock alone shows why next week’s earnings are important. CGC Stock Is Cheap Enough, If … Again, Canopy Growth stock isn’t cheap in terms ... | Why Earnings Matter for the Canopy Growth Stock Price The trajectory of CGC stock alone shows why next week’s earnings are important. CGC Stock Is Cheap Enough, If … Again, Canopy Growth stock isn’t cheap in terms of traditional metrics. A Big Quarter for CGC This is a huge quarter for Canopy Growth stock. | And the issues go beyond CGC stock price. Why Earnings Matter for the Canopy Growth Stock Price The trajectory of CGC stock alone shows why next week’s earnings are important. The case for Canopy Growth stock being reasonably cheap here is that $32 is about what Constellation . |
38243.0 | 2019-08-07 00:00:00 UTC | 3 Things to Know About Aurora Cannabis' Fourth-Quarter Guidance | ACB | https://www.nasdaq.com/articles/3-things-to-know-about-aurora-cannabis-fourth-quarter-guidance-2019-08-07 | nan | nan | Although earnings season never really ends, it's about to ramp up in a big way for the cannabis industry. Among the dozens of pot stocks slated to report in the weeks to come, perhaps none has the attention of Wall Street more than Aurora Cannabis (NYSE: ACB).
The fact that all eyes are on Aurora should surprise absolu... | Among the dozens of pot stocks slated to report in the weeks to come, perhaps none has the attention of Wall Street more than Aurora Cannabis (NYSE: ACB). As larger grow farms come on line, the expectation is that the price per gram to produce marijuana should decline substantially, leading to a healthy uptick in margi... | Among the dozens of pot stocks slated to report in the weeks to come, perhaps none has the attention of Wall Street more than Aurora Cannabis (NYSE: ACB). According to a preliminary review, the company expects to report (Aurora reports in Canadian dollars) between CA$100 million and CA$107 million in net fourth-quarter... | Among the dozens of pot stocks slated to report in the weeks to come, perhaps none has the attention of Wall Street more than Aurora Cannabis (NYSE: ACB). According to a preliminary review, the company expects to report (Aurora reports in Canadian dollars) between CA$100 million and CA$107 million in net fourth-quarter... | Among the dozens of pot stocks slated to report in the weeks to come, perhaps none has the attention of Wall Street more than Aurora Cannabis (NYSE: ACB). Even though Aurora isn't slated to report its quarterly results for weeks, the company did excite Wall Street by providing sales guidance for its fiscal fourth quart... |
38244.0 | 2019-08-07 00:00:00 UTC | Wednesday’s Vital Data: Aurora Cannabis, Starbucks and Beyond Meat | ACB | https://www.nasdaq.com/articles/wednesdays-vital-data%3A-aurora-cannabis-starbucks-and-beyond-meat-2019-08-07 | nan | nan | U.S. stock futures are tracking lower this morning. The weakness will test buyers’ resolve to see if Tuesday’s sharp rebound was a one-off or the beginning of a more sustainable recovery.
Source: Shutterstock
Ahead of the bell, futures on the Dow Jones Industrial Average are down 0.76%, and S&P 500 futures are lower by... | Let’s take a closer look: Aurora Cannabis (ACB) Aurora Cannabis shares rocketed as much as 16% higher yesterday on strong fiscal fourth-quarter guidance. Cooler heads prevailed by day’s end, however, and ACB stock ended the day up 10%. Nonetheless, investors rewarded ACB shares with a hefty gain. | Let’s take a closer look: Aurora Cannabis (ACB) Aurora Cannabis shares rocketed as much as 16% higher yesterday on strong fiscal fourth-quarter guidance. Cooler heads prevailed by day’s end, however, and ACB stock ended the day up 10%. Nonetheless, investors rewarded ACB shares with a hefty gain. | Cooler heads prevailed by day’s end, however, and ACB stock ended the day up 10%. Let’s take a closer look: Aurora Cannabis (ACB) Aurora Cannabis shares rocketed as much as 16% higher yesterday on strong fiscal fourth-quarter guidance. Nonetheless, investors rewarded ACB shares with a hefty gain. | Let’s take a closer look: Aurora Cannabis (ACB) Aurora Cannabis shares rocketed as much as 16% higher yesterday on strong fiscal fourth-quarter guidance. Cooler heads prevailed by day’s end, however, and ACB stock ended the day up 10%. Nonetheless, investors rewarded ACB shares with a hefty gain. |
38245.0 | 2019-08-06 00:00:00 UTC | Why Aurora Cannabis, EverQuote, and Shake Shack Jumped Today | ACB | https://www.nasdaq.com/articles/why-aurora-cannabis-everquote-and-shake-shack-jumped-today-2019-08-06 | nan | nan | Tuesday was a breath of fresh air for investors, as major benchmarks rebounded from their sharp losses on Monday. Despite moves from China to devalue the yuan against the U.S. dollar, the currency market stabilized, giving market participants some comfort that things might not get out of hand too quickly. Good news fro... | Aurora Cannabis (NYSE: ACB), EverQuote (NASDAQ: EVER), and Shake Shack (NYSE: SHAK) were among the top performers. Aurora expects growth in medical and consumer markets both within Canada and internationally, and the company sees production toward the upper end of a range between 25,000 and 30,000 kilos. The online ins... | Aurora Cannabis (NYSE: ACB), EverQuote (NASDAQ: EVER), and Shake Shack (NYSE: SHAK) were among the top performers. The cannabis producer said that it expects to see revenue soar to more than 100 million Canadian dollars, up from just CA$19.1 million in last year's fiscal fourth quarter. Offer from The Motley Fool: The ... | Aurora Cannabis (NYSE: ACB), EverQuote (NASDAQ: EVER), and Shake Shack (NYSE: SHAK) were among the top performers. EverQuote gets a lot of Wall Street love EverQuote's stock soared 49% following a number of positive comments from analyst companies on Wall Street. In addition to favorable commentary from a half-dozen di... | Aurora Cannabis (NYSE: ACB), EverQuote (NASDAQ: EVER), and Shake Shack (NYSE: SHAK) were among the top performers. At least for now, investors like what they're seeing. The company also sees itself scoring better revenue and opening more new stores this year than it previously anticipated. |
38246.0 | 2019-08-06 00:00:00 UTC | Aurora Cannabis Up on Encouraging Q4 Preliminary Results | ACB | https://www.nasdaq.com/articles/aurora-cannabis-up-on-encouraging-q4-preliminary-results-2019-08-06 | nan | nan | Aurora Cannabis (NYSE: ACB), one of the most popular marijuana stocks on the market, today released preliminary, unaudited revenue figures for the company's fourth quarter of fiscal 2019, which concluded at the end of June. These numbers indicate that net revenue for the quarter landed between CA$100 million and CA$107... | Aurora Cannabis (NYSE: ACB), one of the most popular marijuana stocks on the market, today released preliminary, unaudited revenue figures for the company's fourth quarter of fiscal 2019, which concluded at the end of June. The robust anticipated growth is attributed to higher take in all of the company's key business ... | Aurora Cannabis (NYSE: ACB), one of the most popular marijuana stocks on the market, today released preliminary, unaudited revenue figures for the company's fourth quarter of fiscal 2019, which concluded at the end of June. These numbers indicate that net revenue for the quarter landed between CA$100 million and CA$107... | Aurora Cannabis (NYSE: ACB), one of the most popular marijuana stocks on the market, today released preliminary, unaudited revenue figures for the company's fourth quarter of fiscal 2019, which concluded at the end of June. These numbers indicate that net revenue for the quarter landed between CA$100 million and CA$107... | Aurora Cannabis (NYSE: ACB), one of the most popular marijuana stocks on the market, today released preliminary, unaudited revenue figures for the company's fourth quarter of fiscal 2019, which concluded at the end of June. These numbers indicate that net revenue for the quarter landed between CA$100 million and CA$107... |
38247.0 | 2019-08-06 00:00:00 UTC | Cronos Stock: What To Expect From This Week’s Earnings Report | ACB | https://www.nasdaq.com/articles/cronos-stock%3A-what-to-expect-from-this-weeks-earnings-report-2019-08-06 | nan | nan | Since early March, Cronos (NASDAQ:) stock has been slowly burning. Note that the shares have gone from $24 to $14.
Source: Shutterstock
One of the key reasons is that there has been a general bearishness across the cannabis sector. For evidence, look at the selloffs in shares like Canopy Growth Corp (NYSE:), Tilray (NA... | In the prior quarter, the growth ramp was about 120%, with the main driver being the adult-use market in Canada. Some of the capabilities include: microbiology, organic and analytical chemistry, quality control and method development. The company’s $1.8 billion investment from Altria (NYSE:) opens up many opportunities... | Since early March, Cronos (NASDAQ:) stock has been slowly burning. Yet perhaps the biggest event was the $300 million acquisition of Redwood Holding Group LLC. Bottom Line on CRON Stock Going into the quarter, Wall Street remains quite skeptical of CRON stock. | Earnings Preview for Cronos Stock So, what does this all mean for CRON stock? Bottom Line on CRON Stock Going into the quarter, Wall Street remains quite skeptical of CRON stock. All in all, I think CRON stock remains one of the best ways to play the cannabis wave right now. | Earnings Preview for Cronos Stock So, what does this all mean for CRON stock? Yet perhaps the biggest event was the $300 million acquisition of Redwood Holding Group LLC. Bottom Line on CRON Stock Going into the quarter, Wall Street remains quite skeptical of CRON stock. |
38248.0 | 2019-08-05 00:00:00 UTC | ACB Stock May Be Legitimately Undervalued | ACB | https://www.nasdaq.com/articles/acb-stock-may-be-legitimately-undervalued | nan | nan | Cannabis stocks have been drubbed over the past three months. The ETFMG Alternative Harvest ETF (NYSEARCA:), the largest cannabis exchange traded fund (ETF), is lower by 20% over that period, putting it into a bear market. Some marquee cannabis names have performed worse, including Aurora Cannabis Inc. (NYSE:), shares ... | Plus, at ACB’s average pace of trading, it would take roughly seven days to cover all these pessimistic positions.” For investors that just like good old-fashioned fundamentals and intend to be involved with Aurora stock for the long-term, take heart. In an arena known for mostly unprofitable growth companies (ACB stoc... | In an arena known for mostly unprofitable growth companies (ACB stock is a mid-cap growth name), it can be , even when prices tumble. There is good news for ACB stock investors: the company is one of the more quality names in the cannabis space and, in the eyes of some analysts, one of the more attractively-valued. It ... | Plus, at ACB’s average pace of trading, it would take roughly seven days to cover all these pessimistic positions.” For investors that just like good old-fashioned fundamentals and intend to be involved with Aurora stock for the long-term, take heart. In an arena known for mostly unprofitable growth companies (ACB stoc... | There is good news for ACB stock investors: the company is one of the more quality names in the cannabis space and, in the eyes of some analysts, one of the more attractively-valued. In an arena known for mostly unprofitable growth companies (ACB stock is a mid-cap growth name), it can be , even when prices tumble. It ... |
38249.0 | 2019-08-05 00:00:00 UTC | Hexo Stock Is Almost Worth Buying Now | ACB | https://www.nasdaq.com/articles/hexo-stock-is-almost-worth-buying-now | nan | nan | This year, life has come at Hexo (NYSE:) stock fast. After opening the year around $3 a share, the Canadian cannabis company doubled by early February and by early May, the shares resided over $8. Since then, HEXO stock has been drubbed.
Source: Shutterstock
After hitting a 52-week high of $8.40 in early May, HEXO stoc... | Source: Shutterstock After hitting a 52-week high of $8.40 in early May, HEXO stock was cut in half, tumbling to around $4 before surging 10% last week to close around $4.40. I would like to thank the entire team and all our supporters for making this possible.” That’s a lot of public relations speak right there and in... | After opening the year around $3 a share, the Canadian cannabis company doubled by early February and by early May, the shares resided over $8. Three of the four new cannabis ETFs are actively managed funds, meaning there is a manager with discretion over the fund’s holdings and that the fund is not beholden to an inde... | Remember, HEXO is a small-cap stock and small caps are usually pricier than large caps, but at 34x earnings, HEXO stock is richly valued relative to the small-cap Russell 2000 Index, which has a price-to-earnings ratio of 16.74x. While those funds are not excessively allocated to HEXO stock, managers’ allocations to th... | This year, life has come at Hexo (NYSE:) stock fast. Three of the four new cannabis ETFs are actively managed funds, meaning there is a manager with discretion over the fund’s holdings and that the fund is not beholden to an index’s components. Bottom Line on HEXO Stock Over the near-term, HEXO needs to steer clear of ... |
38250.0 | 2019-08-04 00:00:00 UTC | The Concerning Number in Aphria's Fourth-Quarter Report | ACB | https://www.nasdaq.com/articles/the-concerning-number-in-aphrias-fourth-quarter-report-2019-08-04 | nan | nan | Over the past year, we've seen a pretty big, but important, shift in the marijuana industry. No longer are promises good enough for investors to send cannabis stocks higher. Nowadays, with Canada having legalized adult-use marijuana, and two-thirds of U.S. states giving the green light to medical cannabis, earnings act... | Aurora Cannabis (NYSE: ACB), the most popular pot stock, and the most-held stock of any company on investing app Robinhood, has piled up the goodwill after making more than a dozen acquisitions in the past three years. Nowadays, with Canada having legalized adult-use marijuana, and two-thirds of U.S. states giving the ... | Aurora Cannabis (NYSE: ACB), the most popular pot stock, and the most-held stock of any company on investing app Robinhood, has piled up the goodwill after making more than a dozen acquisitions in the past three years. But before your jaw hits the floor, keep in mind that generally lower-margin European distribution re... | Aurora Cannabis (NYSE: ACB), the most popular pot stock, and the most-held stock of any company on investing app Robinhood, has piled up the goodwill after making more than a dozen acquisitions in the past three years. And no, it's not the company's cash balance, which grew to north of CA$570 million in the fourth quar... | Aurora Cannabis (NYSE: ACB), the most popular pot stock, and the most-held stock of any company on investing app Robinhood, has piled up the goodwill after making more than a dozen acquisitions in the past three years. According to the company, it expects between CA$650 million and CA$700 million in sales, of which a l... |
38251.0 | 2019-08-04 00:00:00 UTC | The Concerning Number in Aphria's 4th-Quarter Report | ACB | https://www.nasdaq.com/articles/the-concerning-number-in-aphrias-4th-quarter-report-2019-08-04 | nan | nan | Over the past year, we've seen a pretty big, but important, shift in the marijuana industry. No longer are promises good enough for investors to send cannabis stocks higher. Nowadays, with Canada having legalized adult-use marijuana, and two-thirds of U.S. states giving the green light to medical cannabis, earnings act... | Aurora Cannabis (NYSE: ACB), the most popular pot stock, and the most-held stock of any company on investing app Robinhood, has piled up the goodwill after making more than a dozen acquisitions in the past three years. Nowadays, with Canada having legalized adult-use marijuana, and two-thirds of U.S. states giving the ... | Aurora Cannabis (NYSE: ACB), the most popular pot stock, and the most-held stock of any company on investing app Robinhood, has piled up the goodwill after making more than a dozen acquisitions in the past three years. But before your jaw hits the floor, keep in mind that generally lower-margin European distribution re... | Aurora Cannabis (NYSE: ACB), the most popular pot stock, and the most-held stock of any company on investing app Robinhood, has piled up the goodwill after making more than a dozen acquisitions in the past three years. And no, it's not the company's cash balance, which grew to north of CA$570 million in the fourth quar... | Aurora Cannabis (NYSE: ACB), the most popular pot stock, and the most-held stock of any company on investing app Robinhood, has piled up the goodwill after making more than a dozen acquisitions in the past three years. According to the company, it expects between CA$650 million and CA$700 million in sales, of which a l... |
38252.0 | 2019-08-03 00:00:00 UTC | 4 Cannabis Stocks on Track for at Least 250,000 Kilos of Annual Pot Production | ACB | https://www.nasdaq.com/articles/4-cannabis-stocks-on-track-for-at-least-250000-kilos-of-annual-pot-production-2019-08-03 | nan | nan | Depending on your preferred source, the marijuana industry is set to grow to between $50 billion and $200 billion in annual sales in roughly a decade, give or take a year. Mind you, the worldwide legal weed industry generated "only" $10.9 billion in licensed-store sales last year, demonstrating what a mammoth opportuni... | Aurora Cannabis: At least 667,000 kilos At this point, the undisputed output leader looks to be Edmonton-based Aurora Cannabis (NYSE: ACB), which has 15 separate growing facilities. If and when dried flower oversupply and/or commoditization strikes in Canada, as it's done in a number of recreationally legal U.S. states... | Aurora Cannabis: At least 667,000 kilos At this point, the undisputed output leader looks to be Edmonton-based Aurora Cannabis (NYSE: ACB), which has 15 separate growing facilities. Canopy Growth: More than 500,000 kilos Even though it's the largest cannabis stock by market cap in the world, Canopy Growth (NYSE: CGC) i... | Aurora Cannabis: At least 667,000 kilos At this point, the undisputed output leader looks to be Edmonton-based Aurora Cannabis (NYSE: ACB), which has 15 separate growing facilities. If Aurora's yields are even modestly above projections, or if it were to expand Whistler Pemberton, Aurora Prairie (formerly CanniMed's co... | Aurora Cannabis: At least 667,000 kilos At this point, the undisputed output leader looks to be Edmonton-based Aurora Cannabis (NYSE: ACB), which has 15 separate growing facilities. Canopy Growth: More than 500,000 kilos Even though it's the largest cannabis stock by market cap in the world, Canopy Growth (NYSE: CGC) i... |
38253.0 | 2019-08-03 00:00:00 UTC | 3 Reasons Aphria Might Be the Best Pot Stock to Buy Now | ACB | https://www.nasdaq.com/articles/3-reasons-aphria-might-be-the-best-pot-stock-to-buy-now-2019-08-03 | nan | nan | Canada's third largest marijuana cultivator, Aphria (NYSE: APHA), shocked Wall Street last Friday by posting a huge sales boost during its fiscal fourth quarter. In fact, the company generated a modest profit of CA$15.8 million, or CA$0.05 per share, for the three-month period, thanks to its newly acquired German medic... | Aphria has an attractive valuation Compared to fellow top-tier cultivators Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC), Aphria's shares are a downright bargain. Canada's third largest marijuana cultivator, Aphria (NYSE: APHA), shocked Wall Street last Friday by posting a huge sales boost during its fiscal... | Aphria has an attractive valuation Compared to fellow top-tier cultivators Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC), Aphria's shares are a downright bargain. Canada's third largest marijuana cultivator, Aphria (NYSE: APHA), shocked Wall Street last Friday by posting a huge sales boost during its fiscal... | Aphria has an attractive valuation Compared to fellow top-tier cultivators Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC), Aphria's shares are a downright bargain. All told, Aphria's stock should easily outperform both Aurora and Canopy's respective equities from this point forward, thanks to its rock-bottom... | Aphria has an attractive valuation Compared to fellow top-tier cultivators Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC), Aphria's shares are a downright bargain. In fact, the company generated a modest profit of CA$15.8 million, or CA$0.05 per share, for the three-month period, thanks to its newly acquired... |
38254.0 | 2019-08-02 00:00:00 UTC | At What Price Is Aurora Cannabis Worth Buying? | ACB | https://www.nasdaq.com/articles/at-what-price-is-aurora-cannabis-worth-buying-2019-08-02 | nan | nan | B
y Sean Williams
To investors, the cannabis industry represents the greatest growth opportunity since the rise of the internet a quarter of a century ago. We already know that tens of billions of dollars in illicit cannabis is being purchased yearly through black-market channels, which means strong demand exists. It's... | Topping the list of the most intriguing marijuana stocks is none other than Aurora Cannabis (NYSE: ACB). No matter which investment firm guesses closest, the common denominator on Wall Street is that the marijuana industry can average a double-digit annual growth rate through 2029/2030. With a presence in two dozen mar... | Topping the list of the most intriguing marijuana stocks is none other than Aurora Cannabis (NYSE: ACB). Third -- once again, building on the previous point -- Aurora Cannabis has seen its earnings estimates declining, according to Wall Street forecasts. According to Wall Street, Aurora's fiscal 2020 forecast (ended Ju... | Topping the list of the most intriguing marijuana stocks is none other than Aurora Cannabis (NYSE: ACB). Five catalysts that could send Aurora Cannabis higher I haven't been a fan of Aurora Cannabis for quite some time due to this abundance of negative catalysts. Second, and to add on to the previous point, as Aurora's... | Topping the list of the most intriguing marijuana stocks is none other than Aurora Cannabis (NYSE: ACB). Third -- once again, building on the previous point -- Aurora Cannabis has seen its earnings estimates declining, according to Wall Street forecasts. A fourth catalyst is Aurora's focus on medical cannabis patients. |
38255.0 | 2019-07-31 00:00:00 UTC | Aurora Cannabis Lands a "Prime-Time" Partnership | ACB | https://www.nasdaq.com/articles/aurora-cannabis-lands-a-prime-time-partnership-2019-07-31 | nan | nan | Legal marijuana has more or less been anointed as the next-big-thing investment on Wall Street. After worldwide sales came in at just under $11 billion in 2018, various Wall Street firms have called for anywhere from $50 billion to $200 billion in global annual sales in roughly a decade's time. Regardless of the estima... | That makes marijuana stocks a hot commodity -- and none has been arguably gravitated to more than Edmonton-based Aurora Cannabis (NYSE: ACB). With the exception of Canopy Growth, and perhaps Flowr Corp., which should benefit from its purchase of Holigen and its outdoor grow farm in Portugal, no other global producers a... | That makes marijuana stocks a hot commodity -- and none has been arguably gravitated to more than Edmonton-based Aurora Cannabis (NYSE: ACB). Investors have flocked to this popular cannabis stock Aurora Cannabis is currently the most-held stock on online investing app Robinhood, which is used by approximately 6 million... | That makes marijuana stocks a hot commodity -- and none has been arguably gravitated to more than Edmonton-based Aurora Cannabis (NYSE: ACB). Investors have flocked to this popular cannabis stock Aurora Cannabis is currently the most-held stock on online investing app Robinhood, which is used by approximately 6 million... | That makes marijuana stocks a hot commodity -- and none has been arguably gravitated to more than Edmonton-based Aurora Cannabis (NYSE: ACB). The company has watched as peers like Canopy Growth have secured a $4 billion equity investment from Corona and Modelo beer maker Constellation Brands, and Cronos Group netted a ... |
38256.0 | 2019-07-30 00:00:00 UTC | Why and How You Should Buy Hexo Stock | ACB | https://www.nasdaq.com/articles/why-and-how-you-should-buy-hexo-stock-2019-07-30 | nan | nan | As an investment, it’s been tough being a bull in Hexo (NYSE:) the past few months. Still, could Hexo stock finally be worth the risk and deserving of room in your portfolio today? For that answer, let’s take a look both off and on the price chart to reach a more informed decision.
Source: Shutterstock
Let’s face it, a... | And at the end of the day, Hexo stock and its cannabis peers need regulatory approval and additional markets outside of Canada for longer-term survival and ultimately, be able to thrive. As much, resources from financial support to Molson’s marketing, distribution and operational expertise give Hexo a critical early ad... | Source: Shutterstock Let’s face it, a speculative cannabis market isn’t without its very real challenges for Hexo. But Hexo stock could be offering today’s investors another important ace on the price chart. Hexo Stock Weekly Chart Despite the pressure on the cannabis industry the past few months and HEXO’s own precipi... | And at the end of the day, Hexo stock and its cannabis peers need regulatory approval and additional markets outside of Canada for longer-term survival and ultimately, be able to thrive. Hexo Stock Weekly Chart Despite the pressure on the cannabis industry the past few months and HEXO’s own precipitous corrective move,... | Source: Shutterstock Let’s face it, a speculative cannabis market isn’t without its very real challenges for Hexo. In large part it’s why shares of HEXO have lost 55% of their value with Monday’s low in hand and in just four short months. But Hexo stock could be offering today’s investors another important ace on the p... |
38257.0 | 2019-07-30 00:00:00 UTC | 5 Marijuana Stocks to Buy Before They Rebound | ACB | https://www.nasdaq.com/articles/5-marijuana-stocks-to-buy-before-they-rebound-2019-07-30 | nan | nan | After peaking at close to $12 in March, the truth of the way CannTrust (NYSE:) conducts its business put an end to the sector’s rally. A negative audit resulted in CannTrust suspending cannabis sales.
In effect, the market decided that the cannabis stock no longer belongs in this red-hot sector. Still, speculators may ... | Consider ACB as a marijuana stock to buy. After peaking at close to $12 in March, the truth of the way CannTrust (NYSE:) conducts its business put an end to the sector’s rally. Operating expenses continued to grow after Canopy expanded rapidly in the U.S. Its Acreage Holdings acquisition may give it a path to serve rec... | Consider ACB as a marijuana stock to buy. In the next few quarters, marijuana stocks will trade higher if the underlying company reports higher revenue and shrinking operating costs. Aurora Cannabis Source: Shutterstock Aurora Cannabis (NYSE:) lost nearly 10% in the last month as pot stocks sold off in that period. | Consider ACB as a marijuana stock to buy. In the next few quarters, marijuana stocks will trade higher if the underlying company reports higher revenue and shrinking operating costs. Aurora Cannabis Source: Shutterstock Aurora Cannabis (NYSE:) lost nearly 10% in the last month as pot stocks sold off in that period. | Consider ACB as a marijuana stock to buy. In the next few quarters, marijuana stocks will trade higher if the underlying company reports higher revenue and shrinking operating costs. How will marijuana stocks fare as investors hesitate to speculate in them? |
38258.0 | 2019-07-29 00:00:00 UTC | Marijuana Legalization: How Investors Can Profit! | ACB | https://www.nasdaq.com/articles/marijuana-legalization%3A-how-investors-can-profit-2019-07-29 | nan | nan | If you're not sure where to begin when it comes to capitalizing on cannabis, you're not alone. But it's not hard to learn the legal landscape and develop an understanding of some of the best pot stocks available.
Narrator: Cannabis is the latest hot commodity to take markets by storm, and many public companies are bene... | The biggest marijuana producers, all based in Canada, are Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), Cronos Group and Tilray (NASDAQ: TLRY). While sales likely won't approach that figure in the next ten years, it's still clear this opportunity is huge — and that has investors excited. And MedMen (OTC: MMN... | The biggest marijuana producers, all based in Canada, are Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), Cronos Group and Tilray (NASDAQ: TLRY). And MedMen (OTC: MMNFF) operates North American marijuana dispensaries, and its seven California facilities make more in sales per square foot than Apple or Tiffany ... | The biggest marijuana producers, all based in Canada, are Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), Cronos Group and Tilray (NASDAQ: TLRY). Narrator: Cannabis is the latest hot commodity to take markets by storm, and many public companies are benefiting from global growth in new markets for recreational ... | The biggest marijuana producers, all based in Canada, are Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), Cronos Group and Tilray (NASDAQ: TLRY). Are you ready to invest in pot stocks? Investing in cannabis is a great supplement to an already diversified portfolio, but it shouldn't be the only industry you're ... |
38259.0 | 2019-07-29 00:00:00 UTC | Investing in Cannabis Stocks? Here Are 13 Things You Need to Know | ACB | https://www.nasdaq.com/articles/investing-in-cannabis-stocks-here-are-13-things-you-need-to-know-2019-07-29 | nan | nan | B
y Sean Williams
Though there are literally thousands of stocks for investors to choose from, it's a group of a few dozen in the budding marijuana industry that are garnering a lot of buzz. And it's not hard to see why, either. If investors had the foresight, fortitude, and luck to invest in some of the biggest cannab... | Aurora Cannabis (NYSE: ACB) may lead all growers in annual output, but it's Canopy Growth (NYSE: CGC) that sports nearly double the market cap of Aurora, thanks in part to Canopy Growth's $3.4 billion cash pile and its 70,000 kilos' worth of supply deals with all of Canada's provinces. Just understand that while univer... | Aurora Cannabis (NYSE: ACB) may lead all growers in annual output, but it's Canopy Growth (NYSE: CGC) that sports nearly double the market cap of Aurora, thanks in part to Canopy Growth's $3.4 billion cash pile and its 70,000 kilos' worth of supply deals with all of Canada's provinces. From the low-end estimate from Je... | Aurora Cannabis (NYSE: ACB) may lead all growers in annual output, but it's Canopy Growth (NYSE: CGC) that sports nearly double the market cap of Aurora, thanks in part to Canopy Growth's $3.4 billion cash pile and its 70,000 kilos' worth of supply deals with all of Canada's provinces. The medical benefits of cannabis ... | Aurora Cannabis (NYSE: ACB) may lead all growers in annual output, but it's Canopy Growth (NYSE: CGC) that sports nearly double the market cap of Aurora, thanks in part to Canopy Growth's $3.4 billion cash pile and its 70,000 kilos' worth of supply deals with all of Canada's provinces. There's more to cannabis investin... |
38260.0 | 2019-07-28 00:00:00 UTC | Here's Why the Pot Stock Bubble Hasn't Really Burst | ACB | https://www.nasdaq.com/articles/heres-why-the-pot-stock-bubble-hasnt-really-burst-2019-07-28 | nan | nan | Pot stocks have taken an absolute shellacking in recent months. Just look at the top five Canadian cannabis producers. Shares of Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), Cronos Group (NASDAQ: CRON), Tilray (NASDAQ: TLRY), and Aphria (NYSE: APHA) are all down more than 30% from their highs earlier in the ... | Shares of Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), Cronos Group (NASDAQ: CRON), Tilray (NASDAQ: TLRY), and Aphria (NYSE: APHA) are all down more than 30% from their highs earlier in the year. Aphria CEO Vic Neufeld gave up his executive position after his company battled allegations of drastically overpa... | Shares of Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), Cronos Group (NASDAQ: CRON), Tilray (NASDAQ: TLRY), and Aphria (NYSE: APHA) are all down more than 30% from their highs earlier in the year. The reality is that the long-term prospects for Canopy Growth, Aurora, Cronos, Tilray, and Aphria haven't changed... | Shares of Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), Cronos Group (NASDAQ: CRON), Tilray (NASDAQ: TLRY), and Aphria (NYSE: APHA) are all down more than 30% from their highs earlier in the year. If these predictions are even close to being in the ballpark of how big the cannabis market will be, there's a pr... | Shares of Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), Cronos Group (NASDAQ: CRON), Tilray (NASDAQ: TLRY), and Aphria (NYSE: APHA) are all down more than 30% from their highs earlier in the year. Except for Cronos Group, all four of the other top Canadian pot stocks ended last year more than 50% off of their... |
38261.0 | 2019-07-28 00:00:00 UTC | The 13 Largest Marijuana Stocks in the World | ACB | https://www.nasdaq.com/articles/the-13-largest-marijuana-stocks-in-the-world-2019-07-28 | nan | nan | As recently as April, 17 pure-play pot stocks -- i.e., not the Scotts Miracle-Gros and Altrias of the world that rely on cannabis as a small percentage of their sales -- were lugging around a market cap of at least $1 billion. This was the result of robust growth projections for the marijuana industry that forecast any... | Aurora Cannabis: $6.82 billion Although it's flirted with large-cap territory for short periods of time, Aurora Cannabis (NYSE: ACB) has firmly established itself as the second-largest pot stock by market cap. As recently as April, 17 pure-play pot stocks -- i.e., not the Scotts Miracle-Gros and Altrias of the world th... | Aurora Cannabis: $6.82 billion Although it's flirted with large-cap territory for short periods of time, Aurora Cannabis (NYSE: ACB) has firmly established itself as the second-largest pot stock by market cap. Curaleaf Holdings: $3.67 billion Vertically integrated dispensary operator Curaleaf Holdings (NASDAQOTH: CURLF... | Aurora Cannabis: $6.82 billion Although it's flirted with large-cap territory for short periods of time, Aurora Cannabis (NYSE: ACB) has firmly established itself as the second-largest pot stock by market cap. GW Pharmaceuticals: $4.96 billion The only pure-play cannabinoid-based drug stock on this list, GW Pharmaceuti... | Aurora Cannabis: $6.82 billion Although it's flirted with large-cap territory for short periods of time, Aurora Cannabis (NYSE: ACB) has firmly established itself as the second-largest pot stock by market cap. Canopy Growth: $12.07 billion The biggest cannabis stock by a mile, and the only true large-cap pot stock, con... |
38262.0 | 2019-07-26 00:00:00 UTC | Is the Colombian Cannabis Industry Leading Latin America, Or Just Leading Investors On A Wild Goose Chase? | ACB | https://www.nasdaq.com/articles/is-the-colombian-cannabis-industry-leading-latin-america-or-just-leading-investors-on-a | nan | nan | Every Colombian cannabis company attempts to impress investors and journalists with bombastic rhetoric, claiming to have the largest swath of hectares, the largest amount of registered strains, the highest quality cannabis, the ear of the government, and charitable or social justice initiatives aligned with millennial ... | According to Latin American expert journalist Javier Hasse, other large, publicly traded companies including Aphria (NYSE: APHA), Wayland Group Corp (OTCMKTS: MRRCF), Chemesis International Inc (OTCMKTS: CADMF), Cronos Group (NASDAQ: CRON), and Aurora Cannabis (NYSE: ACB) have also made multi-million dollar investments... | According to Latin American expert journalist Javier Hasse, other large, publicly traded companies including Aphria (NYSE: APHA), Wayland Group Corp (OTCMKTS: MRRCF), Chemesis International Inc (OTCMKTS: CADMF), Cronos Group (NASDAQ: CRON), and Aurora Cannabis (NYSE: ACB) have also made multi-million dollar investments... | According to Latin American expert journalist Javier Hasse, other large, publicly traded companies including Aphria (NYSE: APHA), Wayland Group Corp (OTCMKTS: MRRCF), Chemesis International Inc (OTCMKTS: CADMF), Cronos Group (NASDAQ: CRON), and Aurora Cannabis (NYSE: ACB) have also made multi-million dollar investments... | According to Latin American expert journalist Javier Hasse, other large, publicly traded companies including Aphria (NYSE: APHA), Wayland Group Corp (OTCMKTS: MRRCF), Chemesis International Inc (OTCMKTS: CADMF), Cronos Group (NASDAQ: CRON), and Aurora Cannabis (NYSE: ACB) have also made multi-million dollar investments... |
38263.0 | 2019-07-26 00:00:00 UTC | Is Aphria Stock Worth Buying Ahead of Earnings? | ACB | https://www.nasdaq.com/articles/is-aphria-stock-worth-buying-ahead-of-earnings-2019-07-26 | nan | nan | Canadian cannabis producer Aphria (NYSE:) is set to report its fiscal fourth quarter numbers after the bell on Thursday, August 1. Ahead of that print, Aphria stock price has plunged more than 30% since its last earnings report and APHA stock trades at fresh 2019 lows – while the S&P 500 is making record highs.
In othe... | As of this writing, Luke Lango was long CGC and ACB. Canadian cannabis producer Aphria (NYSE:) is set to report its fiscal fourth quarter numbers after the bell on Thursday, August 1. Investors who don’t mind risk should buy APHA stock before its earnings because it could pop on better-than-expected numbers. | As of this writing, Luke Lango was long CGC and ACB. Canadian cannabis producer Aphria (NYSE:) is set to report its fiscal fourth quarter numbers after the bell on Thursday, August 1. Some of that drag was because of the inclusion of lower margin distribution revenue, but the gross margins of its core cannabis business... | As of this writing, Luke Lango was long CGC and ACB. Ahead of that print, Aphria stock price has plunged more than 30% since its last earnings report and APHA stock trades at fresh 2019 lows – while the S&P 500 is making record highs. Q4 Numbers Could Breathe Life Back Into Aphria Stock Although the cloudy outlook of ... | As of this writing, Luke Lango was long CGC and ACB. Some of that drag was because of the inclusion of lower margin distribution revenue, but the gross margins of its core cannabis business dropped from 50% to 36%. Q4 Numbers Could Breathe Life Back Into Aphria Stock Although the cloudy outlook of APHA stock makes it... |
38264.0 | 2019-07-26 00:00:00 UTC | Cronos Stock Will Benefit From Altria, but Only in the Distant Future | ACB | https://www.nasdaq.com/articles/cronos-stock-will-benefit-from-altria-but-only-in-the-distant-future-2019-07-26 | nan | nan | Cronos (NASDAQ:) stock exists in a state of limbo. Attracting Altria (NYSE:) as an investor has dramatically increased the odds that Cronos will prosper. Also, unlike many marijuana stocks, it has not sold off in recent weeks.
Source: Shutterstock
Production and sales significantly lag not only market leaders but many ... | With a forward price-to-earnings (PE) ratio of 51.77 and the price-to-sales (PS) exceeding 205, CRON stock appears expensive. Today’s marijuana industry is not slow growth, consists mostly of pricey stocks, and gives little thought to payouts as most companies do not turn a profit. With high valuations, dried cannabis ... | Cronos Remains Top-Of-Mind Despite Modest Production Despite lagging sales, CRON stock often gets classified with market leaders Canopy Growth (NYSE:), Aurora Cannabis (NYSE:), and Tilray (NASDAQ:). CRON Stock: Final Thoughts Investors should hold off on CRON stock. With high valuations, dried cannabis prices falling, ... | Cronos Remains Top-Of-Mind Despite Modest Production Despite lagging sales, CRON stock often gets classified with market leaders Canopy Growth (NYSE:), Aurora Cannabis (NYSE:), and Tilray (NASDAQ:). The Direction of CRON Stock Remains Unclear For now, CRON stock has seen one thing that its peers have not in recent week... | Cronos Remains Top-Of-Mind Despite Modest Production Despite lagging sales, CRON stock often gets classified with market leaders Canopy Growth (NYSE:), Aurora Cannabis (NYSE:), and Tilray (NASDAQ:). Currently, CRON stock trades at about $15 per share. CRON Stock: Final Thoughts Investors should hold off on CRON stock. |
38265.0 | 2019-07-26 00:00:00 UTC | Another Big Tobacco Company Invests in Pot -- and Its Partner Might Surprise You | ACB | https://www.nasdaq.com/articles/another-big-tobacco-company-invests-in-pot-and-its-partner-might-surprise-you-2019-07-26 | nan | nan | B
y Keith Speights
Cannabis is attracting the attention of some really big companies outside of the industry. These include major alcoholic beverage makers like Constellation Brands and Molson Coors Brewing. They also include large tobacco companies such as Altria.
Another big tobacco company, Imperial Brands (NASDAQO... | In addition to the added cash, Auxly will be able to use Imperial Brands' vaping technology on a global basis as well as have access to its vapor innovation business, Nerudia. It wouldn't be surprising for the relatively small size of this latest transaction to be attractive to big consumer packaged-goods companies tha... | These include major alcoholic beverage makers like Constellation Brands and Molson Coors Brewing. Another big tobacco company, Imperial Brands (NASDAQOTH: IMBBY), previously dipped its toes into the cannabis waters in 2018 with an investment in British medical marijuana research company Oxford Cannabinoid Technologies.... | Another big tobacco company, Imperial Brands (NASDAQOTH: IMBBY), previously dipped its toes into the cannabis waters in 2018 with an investment in British medical marijuana research company Oxford Cannabinoid Technologies. Potential repercussions Although the investment that Imperial is making in Auxly pales in compari... | They also include large tobacco companies such as Altria. Now, Imperial Brands is investing in a Canadian cannabis producer. Imperial's move could also spur other major companies that aren't tobacco makers to consider investing in cannabis partners. |
38266.0 | 2019-07-26 00:00:00 UTC | Can Investors’ Patience With Aurora Cannabis Stock Be Rewarded Soon? | ACB | https://www.nasdaq.com/articles/can-investors-patience-with-aurora-cannabis-stock-be-rewarded-soon-2019-07-26 | nan | nan | Earlier in July, Canada’s Aurora Cannabis (NYSE:) stock was downgraded to neutral from its previous buy rating, mostly due to concerns over its spending levels and the potential to need funding in the coming quarters. ACB stock price is now hovering around $6.50, the lowest level for 2019.
Source: Shutterstock
At prese... | In addition, ACB’s short-term technical charts, especially the trend lines and support and resistance levels, are telling investors to exercise caution. ACB stock price is now hovering around $6.50, the lowest level for 2019. How ACB Stock Makes Money For cannabis investors, ACB stock needs little introduction. | Other Concerns That May Affect ACB Stock Recent industry developments in Canada have put many investors on alert: Health Canada, the national regulator north of the border, has — due to “unauthorized activities” — revoked both the producer and the dealer licences of Canada-based cannabis producer Agrima Botanicals, whi... | How ACB Stock Makes Money For cannabis investors, ACB stock needs little introduction. If you are considering investing in Aurora Cannabis stock, a front-runner of the marijuana industry and especially the medical segment both in Canada and globally, you may want to start building a position between the $5.5-$6.5 level... | If you are considering investing in Aurora Cannabis stock, a front-runner of the marijuana industry and especially the medical segment both in Canada and globally, you may want to start building a position between the $5.5-$6.5 levels, and expect to hold ACB stock for several years. ACB stock, like its peers, is a vola... |
38267.0 | 2019-07-26 00:00:00 UTC | 5 Reasons Canopy Growth Doesn't Deserve a Lofty Premium | ACB | https://www.nasdaq.com/articles/5-reasons-canopy-growth-doesnt-deserve-a-lofty-premium-2019-07-26 | nan | nan | For years, the marijuana industry has been all the buzz on Wall Street. That's because legal weed could become an industry that generates $100 billion, or perhaps even $200 billion, in annual worldwide sales in a decade, according to various Wall Street forecasts.
But at the center of all this is the largest marijuana ... | Aurora Cannabis' (NYSE: ACB) more than 660,000 kilos look to be the only number ahead of Canopy. This accounts for more than a quarter of Canopy's current market cap, and derives from the $4 billion cash injection it received from Corona and Modelo brewer Constellation Brands (NYSE: STZ), which closed in November. In f... | Aurora Cannabis' (NYSE: ACB) more than 660,000 kilos look to be the only number ahead of Canopy. At this point, Canopy might be one of the last marijuana stocks to push into recurring profitability, likely meaning its war chest of cash will continue to dwindle. Aggressive expansion means ongoing share-based dilution Fi... | Aurora Cannabis' (NYSE: ACB) more than 660,000 kilos look to be the only number ahead of Canopy. It's no secret: Investors really like Canopy Growth There is no shortage of reason Wall Street and investors have placed Canopy Growth on a pedestal above its peers. Canopy Growth's premium could disappear But in spite of i... | Aurora Cannabis' (NYSE: ACB) more than 660,000 kilos look to be the only number ahead of Canopy. That's because legal weed could become an industry that generates $100 billion, or perhaps even $200 billion, in annual worldwide sales in a decade, according to various Wall Street forecasts. It's no secret: Investors real... |
38268.0 | 2019-07-25 00:00:00 UTC | Why You Can Trust ACB Stock Despite This Dip | ACB | https://www.nasdaq.com/articles/why-you-can-trust-acb-stock-despite-this-dip-2019-07-25 | nan | nan | From day one, I have supported marijuana-based investments. Over the long-term, I see tremendous potential in Aurora Cannabis (NYSE:). That said, I must admit candidly that my cheerleading hasn’t been the most accurate. To my chagrin, ACB stock continues to test my patience.
Source: Shutterstock
I’m not just referring ... | To my chagrin, ACB stock continues to test my patience. Another one of my InvestorPlace colleagues, Thomas Niel, discussed the for ACB stock. Additionally, ACB has the strongest international presence: they’re active in across five continents. | To my chagrin, ACB stock continues to test my patience. Another one of my InvestorPlace colleagues, Thomas Niel, discussed the for ACB stock. Additionally, ACB has the strongest international presence: they’re active in across five continents. | Because of the volatility in marijuana stocks broadly, you might assume that none of the core fundamentals will turn positively for ACB stock. To my chagrin, ACB stock continues to test my patience. Another one of my InvestorPlace colleagues, Thomas Niel, discussed the for ACB stock. | Because of the volatility in marijuana stocks broadly, you might assume that none of the core fundamentals will turn positively for ACB stock. To my chagrin, ACB stock continues to test my patience. Another one of my InvestorPlace colleagues, Thomas Niel, discussed the for ACB stock. |
38269.0 | 2019-07-25 00:00:00 UTC | Do Marijuana Stocks Have a Trust Problem? | ACB | https://www.nasdaq.com/articles/do-marijuana-stocks-have-a-trust-problem-2019-07-25 | nan | nan | For years, the marijuana industry has been thriving, and the expectation is that even greener pastures await. After all, according to a recently released report from Arcview Market Research and BDS Analytics, "The State of Legal Cannabis Markets," global weed sales should grow at a better than 24% annual clip through 2... | The most popular pot stock on the planet, Aurora Cannabis (NYSE: ACB), is the poster child of share-based dilution, having increased its outstanding share count by roughly 1 billion over the past five years. Although Canadian pot companies do now have access to loans and lines of credit, U.S. marijuana stocks are still... | The most popular pot stock on the planet, Aurora Cannabis (NYSE: ACB), is the poster child of share-based dilution, having increased its outstanding share count by roughly 1 billion over the past five years. In October, Namaste Technologies was accused of fraud by noted sell-side firm Citron Research, which often holds... | The most popular pot stock on the planet, Aurora Cannabis (NYSE: ACB), is the poster child of share-based dilution, having increased its outstanding share count by roughly 1 billion over the past five years. Cannabis stocks face a wide range of challenges Part of the blame rightly goes to Health Canada in our neighbor ... | The most popular pot stock on the planet, Aurora Cannabis (NYSE: ACB), is the poster child of share-based dilution, having increased its outstanding share count by roughly 1 billion over the past five years. Pot stocks appear to have a trust problem From nearly off-the-radar cannabis stocks to the most popular names in... |
38270.0 | 2019-07-25 00:00:00 UTC | The 3 Pot Stocks You Should Buy, According to This Wall Street Firm | ACB | https://www.nasdaq.com/articles/the-3-pot-stocks-you-should-buy-according-to-this-wall-street-firm-2019-07-25 | nan | nan | Even though the cannabis business has been around for a very long time, at least in illicit form, investors may forget that marijuana is still a nascent industry. There is no precedent to draw upon of an industrialized country legalizing weed, which means there's been a learning curve for investors, the companies invol... | Aurora Cannabis Considering that Ladenburg Thalmann's and Mattson's take on the industry focuses on long-term value creation and market-share gains, perhaps it's no surprise that Aurora Cannabis (NYSE: ACB) is the third pot stock labeled as a buy. There is no precedent to draw upon of an industrialized country legalizi... | Aurora Cannabis Considering that Ladenburg Thalmann's and Mattson's take on the industry focuses on long-term value creation and market-share gains, perhaps it's no surprise that Aurora Cannabis (NYSE: ACB) is the third pot stock labeled as a buy. This past week, Ladenburg Thalmann became the latest Wall Street firm to... | Aurora Cannabis Considering that Ladenburg Thalmann's and Mattson's take on the industry focuses on long-term value creation and market-share gains, perhaps it's no surprise that Aurora Cannabis (NYSE: ACB) is the third pot stock labeled as a buy. Canopy Growth Perhaps one of the biggest surprises is Mattson's and his ... | Aurora Cannabis Considering that Ladenburg Thalmann's and Mattson's take on the industry focuses on long-term value creation and market-share gains, perhaps it's no surprise that Aurora Cannabis (NYSE: ACB) is the third pot stock labeled as a buy. There is no precedent to draw upon of an industrialized country legalizi... |
38271.0 | 2019-07-24 00:00:00 UTC | Ignore the FUD: Aurora Stock Is Still a Must-Own | ACB | https://www.nasdaq.com/articles/ignore-the-fud%3A-aurora-stock-is-still-a-must-own-2019-07-24 | nan | nan | Analyst downgrades can cause market moves, along with a dose of FUD: Fear, Uncertainty, and Doubt. In the case of Aurora Cannabis (NYSE:) stock, one particular analyst was especially harsh on this popular company, causing the share price to decline precipitously.
Source: Shutterstock
If anything, this ought to be viewe... | Again, establishing a multinational footprint will cost money and be a driver of debt, but it’s a savvy investment with the potential to yield stronger earnings and enhanced shareholder value for ACB stockholders. Why ACB Stock Is Under Fire In order to assess whether the criticism of Aurora Cannabis stock is justified... | Is the ACB Stock Criticism Justified? Why ACB Stock Is Under Fire In order to assess whether the criticism of Aurora Cannabis stock is justified, we have to first look at the source, which in this instance is Bank of America Merrill Lynch analyst Christopher Carey. Carey ACB stock from a “buy” rating to “neutral.” He a... | Why ACB Stock Is Under Fire In order to assess whether the criticism of Aurora Cannabis stock is justified, we have to first look at the source, which in this instance is Bank of America Merrill Lynch analyst Christopher Carey. The Bottom Line on Aurora Stock The sadistic side of my investing personality actually enjoy... | Why ACB Stock Is Under Fire In order to assess whether the criticism of Aurora Cannabis stock is justified, we have to first look at the source, which in this instance is Bank of America Merrill Lynch analyst Christopher Carey. Carey ACB stock from a “buy” rating to “neutral.” He also lowered his price target from $10 ... |
38272.0 | 2019-07-24 00:00:00 UTC | Around $35, Tilray Stock Is a Buy | ACB | https://www.nasdaq.com/articles/around-%2435-tilray-stock-is-a-buy-2019-07-24 | nan | nan | It’s hard to believe, but the 52-week high for Tilray (NASDAQ:) is $300. TLRY reached its nose-bleed valuation last October. Except for a couple of rallies, it’s been downhill ever since.
Source: Shutterstock
Trading around $42 as I write this, I still wouldn’t buy it. However, if Tilray stock were to fall into the mid... | By providing an orderly release of 75 million TLRY shares, formerly held by Privateer Holdings, Tilray’s minority shareholders can breathe a sigh of relief that the market won’t be flooded with company stock. As I said in June, the company’s purchase of Manitoba Harvest for $316 million, wasn’t a flashy deal, but it go... | The Latest Tilray News For Tilray stock to move higher, like any other investment, it’s got to provide investors with a catalyst or two. Between June 10 and June 21, TLRY stock moved 17% higher on the news — to $50.45 — only to fall back into the low $40s in July on the lack of a catalyst. My InvestorPlace colleague Lu... | The Latest Tilray News For Tilray stock to move higher, like any other investment, it’s got to provide investors with a catalyst or two. By providing an orderly release of 75 million TLRY shares, formerly held by Privateer Holdings, Tilray’s minority shareholders can breathe a sigh of relief that the market won’t be fl... | The Latest Tilray News For Tilray stock to move higher, like any other investment, it’s got to provide investors with a catalyst or two. Between June 10 and June 21, TLRY stock moved 17% higher on the news — to $50.45 — only to fall back into the low $40s in July on the lack of a catalyst. My InvestorPlace colleague Lu... |
38273.0 | 2019-07-24 00:00:00 UTC | The Only 4 Pot Stocks Worth Considering Long Term | ACB | https://www.nasdaq.com/articles/the-only-4-pot-stocks-worth-considering-long-term-2019-07-24 | nan | nan | When it comes to investing in pot stocks, investors should pull out their history books and read up on the birth of the internet services industry in the late 1990s.
Much like the internet services industry of the late 90’s, the cannabis market of today is a nascent market on the cusp of huge growth over the next ten-p... | Aurora Cannabis (ACB) Source: Shutterstock Next up, we have the cannabis market’s second largest player — Aurora Cannabis (NYSE:) — who, with a little help, could have just as much visibility to long-term cannabis giant status as Canopy. As such, if Aurora can raise a ton of capital within the next several months, ACB ... | Aurora Cannabis (ACB) Source: Shutterstock Next up, we have the cannabis market’s second largest player — Aurora Cannabis (NYSE:) — who, with a little help, could have just as much visibility to long-term cannabis giant status as Canopy. As such, if Aurora can raise a ton of capital within the next several months, ACB ... | Aurora Cannabis (ACB) Source: Shutterstock Next up, we have the cannabis market’s second largest player — Aurora Cannabis (NYSE:) — who, with a little help, could have just as much visibility to long-term cannabis giant status as Canopy. As such, if Aurora can raise a ton of capital within the next several months, ACB ... | Aurora Cannabis (ACB) Source: Shutterstock Next up, we have the cannabis market’s second largest player — Aurora Cannabis (NYSE:) — who, with a little help, could have just as much visibility to long-term cannabis giant status as Canopy. As such, if Aurora can raise a ton of capital within the next several months, ACB ... |
38274.0 | 2019-07-24 00:00:00 UTC | 9 Dividend Stocks to Buy to Suit Any Investing Style | ACB | https://www.nasdaq.com/articles/9-dividend-stocks-to-buy-to-suit-any-investing-style-2019-07-24 | nan | nan | It’s inevitable: no matter where you turn, growth stocks generate the most headlines. Typically, these are companies involved in next-generation technologies. As a result, they simply attract risk-takers wanting to speculate on the next big thing. However, investors with longer-term and more realistic goals should cons... | For one thing, AMTD stock brought steady capital returns, and for good reason: if you want to build wealth, the equity markets offered a simple and intuitive platform. In addition to this critical provision, Welltower brings to the table other highly-demanded services such as post-acute care and outpatient medical solu... | Home Depot (HD) Source: Shutterstock Whenever discussions arise about safe dividend stocks to buy, Home Depot (NYSE:) immediately rises near the top. Exxon Mobil (XOM) Source: Shutterstock Historically, Exxon Mobil (NYSE:) has been one of the best stocks to buy, to the chagrin of drivers everywhere. AMC Entertainment (... | Home Depot (HD) Source: Shutterstock Whenever discussions arise about safe dividend stocks to buy, Home Depot (NYSE:) immediately rises near the top. However, ABBV stock hasn’t been among the best stocks to buy this year; indeed, it’s very much the opposite. But in recent years, MO stock hasn’t really belonged on a lis... | But at the same time, an increasing number of millennials or even grandparents. That said, the company also attracts a lot of criticism. But in recent years, MO stock hasn’t really belonged on a list of best dividend stocks to buy. |
38275.0 | 2019-07-24 00:00:00 UTC | The Most Popular Pot Stock Was Downgraded, but for the Wrong Reason | ACB | https://www.nasdaq.com/articles/the-most-popular-pot-stock-was-downgraded-but-for-the-wrong-reason-2019-07-24 | nan | nan | It's no secret that marijuana stocks are creating quite a lot of buzz on Wall Street. Over the past couple of years, some of the biggest pot stocks by market cap have delivered quadruple-digit-percentage gains, fueling hope that there are other marijuana stocks that could deliver life-changing long-term gains. And the ... | Investors seemingly can't get enough of Aurora Cannabis These challenges aside, it hasn't stopped investors (especially millennials) from buying into Aurora Cannabis (NYSE: ACB), the so-called most popular pot stock. That's because Aurora Cannabis is the most-held stock on online investing app Robinhood, whose approxim... | Investors seemingly can't get enough of Aurora Cannabis These challenges aside, it hasn't stopped investors (especially millennials) from buying into Aurora Cannabis (NYSE: ACB), the so-called most popular pot stock. The most popular pot stock was just downgraded However, these catalysts weren't enough to stop Bank of ... | Investors seemingly can't get enough of Aurora Cannabis These challenges aside, it hasn't stopped investors (especially millennials) from buying into Aurora Cannabis (NYSE: ACB), the so-called most popular pot stock. But with development costs of CA$270 million for its major remaining projects, maintenance costs of exi... | Investors seemingly can't get enough of Aurora Cannabis These challenges aside, it hasn't stopped investors (especially millennials) from buying into Aurora Cannabis (NYSE: ACB), the so-called most popular pot stock. The concern that Carey and his team raised to clients in the rating and price downgrade is that Aurora ... |
38276.0 | 2019-07-23 00:00:00 UTC | Here's How Much Legal Marijuana Canada Has Sold Since Legalizing Adult-Use Cannabis | ACB | https://www.nasdaq.com/articles/heres-how-much-legal-marijuana-canada-has-sold-since-legalizing-adult-use-cannabis-2019-07 | nan | nan | The marijuana industry is expected to be a big-money business, and all eyes are on Canada. That's because Canada became the first industrialized country in the world -- and only the second country overall (behind Uruguay) -- to legalize recreational marijuana this past October.
In the grand scheme of things, Canada isn... | Pot stock quarterly reports should improve, but not by much While it is encouraging to see licensed cannabis sales hit an all-time high three months in a row, this slow-but-steady improvement isn't going to be of significant help to the largest and most popular cannabis stocks, such as Canopy Growth (NYSE: CGC) and Aur... | Pot stock quarterly reports should improve, but not by much While it is encouraging to see licensed cannabis sales hit an all-time high three months in a row, this slow-but-steady improvement isn't going to be of significant help to the largest and most popular cannabis stocks, such as Canopy Growth (NYSE: CGC) and Aur... | Pot stock quarterly reports should improve, but not by much While it is encouraging to see licensed cannabis sales hit an all-time high three months in a row, this slow-but-steady improvement isn't going to be of significant help to the largest and most popular cannabis stocks, such as Canopy Growth (NYSE: CGC) and Aur... | Pot stock quarterly reports should improve, but not by much While it is encouraging to see licensed cannabis sales hit an all-time high three months in a row, this slow-but-steady improvement isn't going to be of significant help to the largest and most popular cannabis stocks, such as Canopy Growth (NYSE: CGC) and Aur... |
38277.0 | 2019-07-22 00:00:00 UTC | 5 Top Stock Trades for Tuesday: ACB, BYND, MU | ACB | https://www.nasdaq.com/articles/5-top-stock-trades-for-tuesday%3A-acb-bynd-mu-2019-07-22 | nan | nan | After a bruising close on Friday, U.S. stocks bounced back a bit on Monday. That’s as investors gear up for some big-time earnings reports later this week. By individual stock standards, the mellow trading days this week are over once we hit Tuesday. Let’s look at some top stock trades going forward.
Top Stock Trades f... | While this one may be too risky for investors to hold outright short, I wouldn’t be long until ACB either gets significantly cheaper or it can clear overhead resistance. On Friday we said the stock is breaking out and on Monday we’re seeing a big move higher on a Goldman Sachs upgrade. I love this name, as it made a pe... | While this one may be too risky for investors to hold outright short, I wouldn’t be long until ACB either gets significantly cheaper or it can clear overhead resistance. Top Stock Trades for Tomorrow #1: Aurora Cannabis Earlier this month developing in Aurora Cannabis (NYSE:), which was a bearish descending triangle. T... | While this one may be too risky for investors to hold outright short, I wouldn’t be long until ACB either gets significantly cheaper or it can clear overhead resistance. Top Stock Trades for Tomorrow #2: Beyond Meat Shares of Beyond Meat (NYSE:) will report earnings on July 29th, but the stock is heating up on Monday, ... | While this one may be too risky for investors to hold outright short, I wouldn’t be long until ACB either gets significantly cheaper or it can clear overhead resistance. Top Stock Trades for Tomorrow #2: Beyond Meat Shares of Beyond Meat (NYSE:) will report earnings on July 29th, but the stock is heating up on Monday, ... |
38278.0 | 2019-07-22 00:00:00 UTC | Why Now Is the Time to Get Long Aurora Cannabis | ACB | https://www.nasdaq.com/articles/why-now-is-the-time-to-get-long-aurora-cannabis-2019-07-22 | nan | nan | Aurora Cannabis (NYSE:) shares are well off the highs in March, but it looks like the tides could be changing for the Canadian cannabis producer.
Source: Shutterstock
As it becomes clearer to the market that Aurora is best-in-class in terms of product innovation, production capacity, and overall footprint, ACB stock sh... | Establishing consistency in meeting demand and with a superior product means more medical and consumer companies are likely to partner with ACB over other competitors. As a result of the 18 strategic acquisitions up and down the value chain ACB has completed over the past three years, they now have a comprehensive port... | Source: Shutterstock As it becomes clearer to the market that Aurora is best-in-class in terms of product innovation, production capacity, and overall footprint, ACB stock shareholders are primed to watch their investments appreciate. Establishing consistency in meeting demand and with a superior product means more med... | Source: Shutterstock As it becomes clearer to the market that Aurora is best-in-class in terms of product innovation, production capacity, and overall footprint, ACB stock shareholders are primed to watch their investments appreciate. Establishing consistency in meeting demand and with a superior product means more med... | Source: Shutterstock As it becomes clearer to the market that Aurora is best-in-class in terms of product innovation, production capacity, and overall footprint, ACB stock shareholders are primed to watch their investments appreciate. As a result of the 18 strategic acquisitions up and down the value chain ACB has comp... |
38279.0 | 2019-07-22 00:00:00 UTC | 1 Incredibly Cheap Pot Stock Worth Buying Now | ACB | https://www.nasdaq.com/articles/1-incredibly-cheap-pot-stock-worth-buying-now-2019-07-22 | nan | nan | Pot stocks have been outstanding growth vehicles for the better part of the past two years. The legalization of adult-use marijuana in Canada, the slow but steady march toward widespread legalization in the United States, and the 2018 Farm Bill -- that essentially legalized hemp -- all helped to drive valuations higher... | OrganiGram's core value proposition and key risk factors OrganiGram has five key pillars to its underlying investing thesis: Near-industry low cost of production due to a unique three-tier indoor growing system, customized automated packaging equipment, and a proprietary information technology system called OrganiGrow ... | In particular, Canada's OrganiGram Holdings Inc. (NASDAQ: OGI) comes across as an outstanding bargain at current levels. In fact, OrganiGram is one of only two Canadian licensed producers currently exploring the production of cannabinoids via biosynthesis. OrganiGram, after all, sports a best-in-class growing platform,... | OrganiGram's core value proposition and key risk factors OrganiGram has five key pillars to its underlying investing thesis: Near-industry low cost of production due to a unique three-tier indoor growing system, customized automated packaging equipment, and a proprietary information technology system called OrganiGrow ... | Should cannabis investors pounce on this cheap pot stock? OrganiGram, after all, sports a best-in-class growing platform, top-notch dried flower strains, and a forward-looking approach to value creation. The Motley Fool recommends OrganiGram Holdings. |
38280.0 | 2019-07-22 00:00:00 UTC | Aurora Cannabis Stock Has a Cash Burn Problem | ACB | https://www.nasdaq.com/articles/aurora-cannabis-stock-has-a-cash-burn-problem-2019-07-22 | nan | nan | The fairy-tale 2019 for Aurora Cannabis (NYSE: ) stock appears to be over. ACB stock roughly doubled in the first three months of the year. It’s now down 22% in the past three months. On Thursday, the slide was capped off by a downgrade from Bank of America.
Source: Shutterstock
At this point, ACB stock is a risky bet... | At this point, it’s nearly impossible to tell which companies that will be Investors can pick ACB stock as the winner and then lose sleep over its high cash burn and balance sheet. ACB stock roughly doubled in the first three months of the year. Source: Shutterstock At this point, ACB stock is a risky bet, given the co... | How to Play ACB Stock Dealing with Aurora Cannabis stock is tricky at this point As Bank of America’s Carey said, there’s nothing wrong with Aurora’s core business. ACB stock roughly doubled in the first three months of the year. Source: Shutterstock At this point, ACB stock is a risky bet, given the company’s clear, ... | To make matters worse, Aurora has a C$230 million convertible debenture that expires in Q1 of 2020 at a share price about 35% above the current level of ACB stock In other words, unless Aurora stock rallies tremendously in the next couple of quarters, Aurora will be on the hook for a C$230 million cash payment in roug... | How to Play ACB Stock Dealing with Aurora Cannabis stock is tricky at this point As Bank of America’s Carey said, there’s nothing wrong with Aurora’s core business. ACB stock roughly doubled in the first three months of the year. Source: Shutterstock At this point, ACB stock is a risky bet, given the company’s clear, ... |
38281.0 | 2019-07-22 00:00:00 UTC | Will Aurora, Canopy, Cronos, and Tilray Be Profitable by 2021? | ACB | https://www.nasdaq.com/articles/will-aurora-canopy-cronos-and-tilray-be-profitable-by-2021-2019-07-22 | nan | nan | Over the next decade, you'd struggle to find an industry that offers the growth potential of legal cannabis. Unlike new technologies, cannabis has been around for a long time and is a proven industry – at least in the black market, where tens of billions of dollars in sales are conducted each year. It wouldn't be all t... | When many of the most popular pot stocks, such as Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), Cronos Group (NASDAQ: CRON), and Tiray (NASDAQ: TLRY), lift the hood on their quarterly performances, Wall Street and investors pay close attention. Although estimates vary quite a bit on Wall Street, the consensus... | When many of the most popular pot stocks, such as Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), Cronos Group (NASDAQ: CRON), and Tiray (NASDAQ: TLRY), lift the hood on their quarterly performances, Wall Street and investors pay close attention. Cronos Group Maybe the biggest question mark of these four pot st... | When many of the most popular pot stocks, such as Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), Cronos Group (NASDAQ: CRON), and Tiray (NASDAQ: TLRY), lift the hood on their quarterly performances, Wall Street and investors pay close attention. Canopy Growth Canopy Growth may be the largest marijuana stock in... | When many of the most popular pot stocks, such as Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), Cronos Group (NASDAQ: CRON), and Tiray (NASDAQ: TLRY), lift the hood on their quarterly performances, Wall Street and investors pay close attention. Even with Aurora Nordic 2 perfectly situated to supply the Scandi... |
38282.0 | 2019-07-21 00:00:00 UTC | The Absurdity of Aurora Cannabis' Latest Analyst Downgrade | ACB | https://www.nasdaq.com/articles/the-absurdity-of-aurora-cannabis-latest-analyst-downgrade-2019-07-21 | nan | nan | Aurora Cannabis (NYSE: ACB) emerged as one of analysts' favorite marijuana stocks earlier this year. In March, Cowen analyst Vivien Azer picked Aurora as her top pot stock. Other analysts jumped on the Aurora bandwagon as well, including Bank of America Merrill Lynch's Christopher Carey.
But Carey recently downgraded A... | Aurora Cannabis (NYSE: ACB) emerged as one of analysts' favorite marijuana stocks earlier this year. Had Carey's original price target been achieved, Aurora wouldn't have had to pay off the convertible debentures that are coming due in early 2020. That's why the company filed a shelf registration earlier this year (bef... | Aurora Cannabis (NYSE: ACB) emerged as one of analysts' favorite marijuana stocks earlier this year. He noted to Bank of America Merrill Lynch (BAML) clients that Aurora is "burning cash." Had Carey's original price target been achieved, Aurora wouldn't have had to pay off the convertible debentures that are coming due... | Aurora Cannabis (NYSE: ACB) emerged as one of analysts' favorite marijuana stocks earlier this year. But Carey recently downgraded Aurora to neutral only three months after initiating coverage on the stock with a buy recommendation. However, Carey doesn't think that Aurora Cannabis stock is one that he can recommend bu... | Aurora Cannabis (NYSE: ACB) emerged as one of analysts' favorite marijuana stocks earlier this year. However, Carey doesn't think that Aurora Cannabis stock is one that he can recommend buying now. But Aurora would have needed to raise more cash regardless of what happened with the convertible debenture. |
38283.0 | 2019-07-19 00:00:00 UTC | Analyst Downgrade Weighs on Aurora Cannabis Stock | ACB | https://www.nasdaq.com/articles/analyst-downgrade-weighs-on-aurora-cannabis-stock-2019-07-20 | nan | nan | Aurora Cannabis (NYSE: ACB) ended Friday down more than peer marijuana stocks, as the market digested news of an analyst downgrade.
Yesterday, it was reported that Bank of America Merrill Lynch analyst Christopher Carey cut his recommendation on Aurora to neutral from buy. Although he still finds things to admire about... | Aurora Cannabis (NYSE: ACB) ended Friday down more than peer marijuana stocks, as the market digested news of an analyst downgrade. Yesterday, it was reported that Bank of America Merrill Lynch analyst Christopher Carey cut his recommendation on Aurora to neutral from buy. In fact, one happy piece of news was announced... | Aurora Cannabis (NYSE: ACB) ended Friday down more than peer marijuana stocks, as the market digested news of an analyst downgrade. Yesterday, it was reported that Bank of America Merrill Lynch analyst Christopher Carey cut his recommendation on Aurora to neutral from buy. In fact, one happy piece of news was announced... | Aurora Cannabis (NYSE: ACB) ended Friday down more than peer marijuana stocks, as the market digested news of an analyst downgrade. In fact, one happy piece of news was announced just prior to the Merrill recommendation cut: the company's victory in a tender conducted by the Italian government to supply medical cannabi... | Aurora Cannabis (NYSE: ACB) ended Friday down more than peer marijuana stocks, as the market digested news of an analyst downgrade. Merrill Lynch is one of the more influential investment banks on the scene, so the opinions of their analysts often carry a lot of weight with institutional and individual investors. In fa... |
38284.0 | 2019-07-19 00:00:00 UTC | Aurora Cannabis Stock: Show Me the Money | ACB | https://www.nasdaq.com/articles/aurora-cannabis-stock%3A-show-me-the-money-2019-07-19 | nan | nan | Locating a bottom is never easy, but right now a cheaper-priced Aurora Cannabis (NYSE:) may finally mean better value for ACB stock bulls. Once more, though, a “show me the money” reversal-based strategy on the price chart looks like smart business. Let me explain.
Source: Shutterstock
It has been a hair under a month ... | Nevertheless and unlike Canopy Growth (NYSE:) — which I remain bearish on — it’s once again time to put ACB stock on the radar for purchase, if a meaningful bottom on the price chart can be established. At the end of the day BofA’s caution may be on the right side of ACB’s longer-term price action, as broken support co... | At last week’s lows, ACB stock had seen an overall correction of 47% from last October’s all-time-high. ACB Stock Weekly Chart Currently, what has caught my attention in ACB stock is a test of the 62% retracement level from last December’s low to 2019’s March high. In this instance, going long ACB stock is strictly bas... | Nevertheless and unlike Canopy Growth (NYSE:) — which I remain bearish on — it’s once again time to put ACB stock on the radar for purchase, if a meaningful bottom on the price chart can be established. ACB Stock Weekly Chart Currently, what has caught my attention in ACB stock is a test of the 62% retracement level fr... | ACB Stock Weekly Chart Currently, what has caught my attention in ACB stock is a test of the 62% retracement level from last December’s low to 2019’s March high. Locating a bottom is never easy, but right now a cheaper-priced Aurora Cannabis (NYSE:) may finally mean better value for ACB stock bulls. Source: Shutterstoc... |
38285.0 | 2019-07-18 00:00:00 UTC | Aurora Cannabis Stock Gets Downgraded | ACB | https://www.nasdaq.com/articles/aurora-cannabis-stock-gets-downgraded-2019-07-18 | nan | nan | Shares of Aurora Cannabis (NYSE: ACB) sank on Thursday after Bank of America analyst Christopher Carey raised concerns regarding the marijuana producer's shrinking cash position. The stock was down 6% at 2:15 p.m. EDT.
Carey downgraded Aurora Cannabis' stock from buy to neutral and lowered his price target from $10 to... | Shares of Aurora Cannabis (NYSE: ACB) sank on Thursday after Bank of America analyst Christopher Carey raised concerns regarding the marijuana producer's shrinking cash position. "Aurora has emerged as one of the best operators in the cannabis sector, with industry-leading scale and margins even versus other large peer... | Shares of Aurora Cannabis (NYSE: ACB) sank on Thursday after Bank of America analyst Christopher Carey raised concerns regarding the marijuana producer's shrinking cash position. Carey downgraded Aurora Cannabis' stock from buy to neutral and lowered his price target from $10 to $8. Bank of America analyst Christopher ... | Shares of Aurora Cannabis (NYSE: ACB) sank on Thursday after Bank of America analyst Christopher Carey raised concerns regarding the marijuana producer's shrinking cash position. However, Carey argues that for Aurora, raising cash to rebuild its reserves is less attractive than using that money to enter new growth mark... | Shares of Aurora Cannabis (NYSE: ACB) sank on Thursday after Bank of America analyst Christopher Carey raised concerns regarding the marijuana producer's shrinking cash position. Still, Carey is concerned that despite Aurora's efforts to improve its profitability, its expansion initiatives are burning through the compa... |
38286.0 | 2019-07-18 00:00:00 UTC | Stock Market News: Aurora Gets Burned; IBM Gets Over the Blues | ACB | https://www.nasdaq.com/articles/stock-market-news%3A-aurora-gets-burned-ibm-gets-over-the-blues-2019-07-18 | nan | nan | Thursday marked another move forward for earnings season, as a rising number of companies will report their latest results over the next couple of weeks. Yet as we've seen throughout much of this week, major stock market indexes didn't have huge responses to earnings or other news, merely easing modestly lower. As of 1... | For Aurora Cannabis (NYSE: ACB), the potential of the marijuana industry is undeniable, but shareholders are concerned about whether the cannabis cultivator will emerge as a winner in the budding field. The analysts praised Aurora's success in building up a huge cannabis operation that has international scope, and the ... | For Aurora Cannabis (NYSE: ACB), the potential of the marijuana industry is undeniable, but shareholders are concerned about whether the cannabis cultivator will emerge as a winner in the budding field. Yet as we've seen throughout much of this week, major stock market indexes didn't have huge responses to earnings or ... | For Aurora Cannabis (NYSE: ACB), the potential of the marijuana industry is undeniable, but shareholders are concerned about whether the cannabis cultivator will emerge as a winner in the budding field. Meanwhile, IBM (NYSE: IBM) has been under pressure for years, but even though Big Blue's revenue has continued to dec... | For Aurora Cannabis (NYSE: ACB), the potential of the marijuana industry is undeniable, but shareholders are concerned about whether the cannabis cultivator will emerge as a winner in the budding field. Meanwhile, IBM (NYSE: IBM) has been under pressure for years, but even though Big Blue's revenue has continued to dec... |
38287.0 | 2019-07-18 00:00:00 UTC | The Growth of Aurora Has Largely Come at the Expense of ACB Stock | ACB | https://www.nasdaq.com/articles/the-growth-of-aurora-has-largely-come-at-the-expense-of-acb-stock-2019-07-18 | nan | nan | Aurora Cannabis (NYSE:) stock has steadily declined since late March. At a time when the S&P 500 continues to make new record highs, ACB stock and marijuana stocks in general have moved in the other direction. The industry has suffered after Canopy Growth (NYSE:) fired its co-CEO and regulators caught CannTrust (NYSE:)... | ACB Remains an Expensive, High-Growth Equity The dilution has helped to take the price of Aurora Cannabis stock down by almost 28% over the last four months, and by nearly 43% from its highs of last October. Moreover, analysts, on average, expect revenue growth for Aurora of almost 385% this year and over 156% in 2020.... | Also, despite a recent pullback, ACB stock and other cannabis equities trade at high valuations. Aurora Cannabis Versus ACB stock Investors should not view Aurora Cannabis and ACB as identical entities. However, the company has financed its growth by significantly diluting ACB stock. | Aurora Cannabis Versus ACB stock Investors should not view Aurora Cannabis and ACB as identical entities. Aurora Is Financing Its Operations With ACB Stock Even if Aurora stock price remains the same, it will still have an elevated price-sales (PS) ratio. Final Thoughts on ACB Stock But Aurora Cannabis will likely serv... | Aurora Cannabis Versus ACB stock Investors should not view Aurora Cannabis and ACB as identical entities. However, by that time, marijuana stocks like ACB will probably resemble the equities of the large companies that are investing in them now. However, the company has financed its growth by significantly diluting ACB... |
38288.0 | 2019-07-18 00:00:00 UTC | 3 Reasons Investors Should Be High on Hexo Stock | ACB | https://www.nasdaq.com/articles/3-reasons-investors-should-be-high-on-hexo-stock-2019-07-18 | nan | nan | When the year started, Hexo (NYSEAMERICAN:) stock got off to a nice start. The shares went from $5 to $8 — riding the cannabis bull wave spurred by the legalization in Canada. But unfortunately, the expectations were too exuberant. Since late April, the HEXO stock price has gone into reverse; right back to $5.
Source: ... | This will put the company in a rare group, with only two other cannabis operators (CGS and ACB). And to see why let’s take a look at the following catalysts: HEXO Stock: Scale While at an investor conference, Tilray (NASDAQ:) CEO Brendan Kennedy and CFO Mark Castaneda provided some interesting insights about the cannab... | This will put the company in a rare group, with only two other cannabis operators (CGS and ACB). Various other cannabis stocks have also been in the downtrend, such as Canopy Growth (NYSE:), Aurora Cannabis (NYSE:) and Cronos Group (NASDAQ:). The company reported revenues of 13.02 million CAD, compared to the Street es... | This will put the company in a rare group, with only two other cannabis operators (CGS and ACB). And to see why let’s take a look at the following catalysts: HEXO Stock: Scale While at an investor conference, Tilray (NASDAQ:) CEO Brendan Kennedy and CFO Mark Castaneda provided some interesting insights about the cannab... | This will put the company in a rare group, with only two other cannabis operators (CGS and ACB). Various other cannabis stocks have also been in the downtrend, such as Canopy Growth (NYSE:), Aurora Cannabis (NYSE:) and Cronos Group (NASDAQ:). And to see why let’s take a look at the following catalysts: HEXO Stock: Scal... |
38289.0 | 2019-07-17 00:00:00 UTC | 3 Reasons Why HEXO Stock Is the Real Deal | ACB | https://www.nasdaq.com/articles/3-reasons-why-hexo-stock-is-the-real-deal-2019-07-17 | nan | nan | There will always be naysayers in the sphere of stock market investing, especially when it comes to cannabis stocks. This is true for the bigger names like Canopy Growth Corp (NYSE:) and Aurora Cannabis (NYSE:). And it also applies to today’s spotlight name, Hexo (NYSE:). But does Hexo stock deserve its reputation as a... | One of the biggest licensed cannabis companies in Canada, Hexo Corp serves both the adult-use and medical-use Canadian markets through a multitude of popular brands. In a landmark agreement with Molson Coors Brewing Company (NYSE:), Hexo moved even faster than Canopy to map out a definitive plan to bring cannabis-enhan... | This is true for the bigger names like Canopy Growth Corp (NYSE:) and Aurora Cannabis (NYSE:). One of the biggest licensed cannabis companies in Canada, Hexo Corp serves both the adult-use and medical-use Canadian markets through a multitude of popular brands. In a landmark agreement with Molson Coors Brewing Company (... | He that Hexo Corp is “extremely pleased to list on the NYSE and believe it reaffirms HEXO’s strong track-record for exceptional corporate governance and is further proof that we are a valuable cannabis industry partner for Fortune 500 companies.” I’d affirm that just like Canopy and Aurora, Hexo deserves to play on the... | There will always be naysayers in the sphere of stock market investing, especially when it comes to cannabis stocks. This is true for the bigger names like Canopy Growth Corp (NYSE:) and Aurora Cannabis (NYSE:). A Major Acquisition In what I believe to be a game-changing expansion, Hexo Corp what was one of my favorite... |
38290.0 | 2019-07-17 00:00:00 UTC | 3 Puny Pot Stocks That Can Grow a Whole Lot of Weed | ACB | https://www.nasdaq.com/articles/3-puny-pot-stocks-that-can-grow-a-whole-lot-of-weed-2019-07-17 | nan | nan | Production isn't everything when examining cannabis stocks, but it's probably the first factor a lot of investors consider when beginning to analyze the space. There's long been the idea that higher levels of production will lead to better profitability, which isn't always the case.
Nevertheless, it should come as litt... | Aurora Cannabis (NYSE: ACB), the projected leading grower by peak capacity with over 660,000 kilos per year when fully operational, is the most-held stock on online investing app Robinhood, which is popular among millennial investors. As you can probably tell by the company's diminutive market cap, investors are still ... | Aurora Cannabis (NYSE: ACB), the projected leading grower by peak capacity with over 660,000 kilos per year when fully operational, is the most-held stock on online investing app Robinhood, which is popular among millennial investors. This acquisition makes Flowr a major global pot grower, which isn't too bad for a com... | Aurora Cannabis (NYSE: ACB), the projected leading grower by peak capacity with over 660,000 kilos per year when fully operational, is the most-held stock on online investing app Robinhood, which is popular among millennial investors. While this all sounds great, 50,000 kilos of premium and ultra-premium flower, plus a... | Aurora Cannabis (NYSE: ACB), the projected leading grower by peak capacity with over 660,000 kilos per year when fully operational, is the most-held stock on online investing app Robinhood, which is popular among millennial investors. Meanwhile, Canopy Growth is the 11th-most-held stock on Robinhood, and is the largest... |
38291.0 | 2019-07-16 00:00:00 UTC | 7 Reasons Aurora, Canopy, Cronos, and HEXO Are All At or Near 6-Month Lows | ACB | https://www.nasdaq.com/articles/7-reasons-aurora-canopy-cronos-and-hexo-are-all-at-or-near-6-month-lows-2019-07-16 | nan | nan | For years, the marijuana industry has been "kicking bud" and taking names. Between 2014 and 2018, the duo of Arcview Market Research and BDS Analytics finds that global licensed cannabis sales have grown from $3.4 billion to $10.9 billion, which gives validity that certain pie-in-the-sky sales projections offered up by... | Investors' favorite pot stocks have been clobbered Last week, the four most popular marijuana stocks on the planet -- Aurora Cannabis (NYSE: ACB), Cronos Group (NASDAQ: CRON), Canopy Growth (NYSE: CGC), and HEXO (NYSEMKT: HEXO) -- all either hit levels last seen in January 2019 or came very close to doing so. Even thou... | Investors' favorite pot stocks have been clobbered Last week, the four most popular marijuana stocks on the planet -- Aurora Cannabis (NYSE: ACB), Cronos Group (NASDAQ: CRON), Canopy Growth (NYSE: CGC), and HEXO (NYSEMKT: HEXO) -- all either hit levels last seen in January 2019 or came very close to doing so. High-marg... | Investors' favorite pot stocks have been clobbered Last week, the four most popular marijuana stocks on the planet -- Aurora Cannabis (NYSE: ACB), Cronos Group (NASDAQ: CRON), Canopy Growth (NYSE: CGC), and HEXO (NYSEMKT: HEXO) -- all either hit levels last seen in January 2019 or came very close to doing so. Following... | Investors' favorite pot stocks have been clobbered Last week, the four most popular marijuana stocks on the planet -- Aurora Cannabis (NYSE: ACB), Cronos Group (NASDAQ: CRON), Canopy Growth (NYSE: CGC), and HEXO (NYSEMKT: HEXO) -- all either hit levels last seen in January 2019 or came very close to doing so. Sure, the... |
38292.0 | 2019-07-15 00:00:00 UTC | 1 Top Cannabis Stock You Can Buy and Hold for the Next Decade | ACB | https://www.nasdaq.com/articles/1-top-cannabis-stock-you-can-buy-and-hold-for-the-next-decade-2019-07-15 | nan | nan | The cannabis industry is expanding at a torrid clip. Investment bank Cowen expects global cannabis sales to grow to $75 billion by 2030, while Bank of America analysts believe the marijuana market could one day generate $166 billion in annual sales.
One marijuana company, Aurora Cannabis (NYSE: ACB), is particularly we... | One marijuana company, Aurora Cannabis (NYSE: ACB), is particularly well positioned to capture a substantial portion of the industry's profits in the coming decade. Constellation Brands and Altria hold warrants that give them the right to increase their ownership stakes in Canopy Growth and Cronos Group in the future, ... | One marijuana company, Aurora Cannabis (NYSE: ACB), is particularly well positioned to capture a substantial portion of the industry's profits in the coming decade. Investment bank Cowen expects global cannabis sales to grow to $75 billion by 2030, while Bank of America analysts believe the marijuana market could one d... | One marijuana company, Aurora Cannabis (NYSE: ACB), is particularly well positioned to capture a substantial portion of the industry's profits in the coming decade. Unlike peers Canopy Growth and Cronos Group (NASDAQ: CRON), which sold equity stakes in their businesses to Constellation Brands (NYSE: STZ) and Altria (NY... | One marijuana company, Aurora Cannabis (NYSE: ACB), is particularly well positioned to capture a substantial portion of the industry's profits in the coming decade. Its closest competitor, Canopy Growth, has operations in only 16 countries. That's important, as the international cannabis market is projected to become m... |
38293.0 | 2019-07-15 00:00:00 UTC | The NYSE Listing Means Legitimacy and Bigger Things for Hexo Stock | ACB | https://www.nasdaq.com/articles/the-nyse-listing-means-legitimacy-and-bigger-things-for-hexo-stock-2019-07-15 | nan | nan | It’s a news item that may have nonchalantly passed over many traditionally minded investors’ radars. In a few days, Hexo (AMEX:) will trade on the grandest stage of all: the New York Stock Exchange. Therefore, even though the HEXO stock price incurred ugly volatility in recent months, that could soon change for the bet... | Instead, the grand prize is full legalization in the U.S. And stories like HEXO being listed in the NYSE add more leverage and credibility to this prospect. With enough positive headlines, the narrative can quickly shift from cannabis firms not making their numbers to potentially advantaging an unprecedented opportunit... | With the “upgrade” in Hexo, the organization joins powerhouse names like Canopy Growth (NYSE:) and Aurora Cannabis (NYSE:). Good News Is Gold for HEXO Stock Despite the above points, I may still have some doubters regarding the NYSE move’s importance. Nevertheless, it’s still a positive development for the budding comp... | With the “upgrade” in Hexo, the organization joins powerhouse names like Canopy Growth (NYSE:) and Aurora Cannabis (NYSE:). Good News Is Gold for HEXO Stock Despite the above points, I may still have some doubters regarding the NYSE move’s importance. Ample Evidence Points to Full Legalization Several years from now, I... | But that’s also the draw for Hexo stock: the NYSE won’t let just anyone in. Good News Is Gold for HEXO Stock Despite the above points, I may still have some doubters regarding the NYSE move’s importance. Nevertheless, it’s still a positive development for the budding company, and good news in this sector is worth its w... |
38294.0 | 2019-07-13 00:00:00 UTC | Marijuana Sales to Hit $200 Billion in a Decade, Wall Street Firm Suggests | ACB | https://www.nasdaq.com/articles/marijuana-sales-to-hit-%24200-billion-in-a-decade-wall-street-firm-suggests-2019-07-13 | nan | nan | Although the marijuana industry has seen its hiccups of late, long-term pot stock investors have little to complain about. Investors with the foresight, wherewithal, and luck to buy into some of the most popular marijuana stocks have seen enormous gains in recent years. And based on the potential of the industry, this ... | Aurora Cannabis (NYSE: ACB), the only Canadian grower that's expected to produce more weed per year at peak capacity than Canopy Growth, is one such name that could thrive internationally. The report put out by Carter to clients suggests that Canada offers the most intriguing near-term opportunity, primarily because it... | Aurora Cannabis (NYSE: ACB), the only Canadian grower that's expected to produce more weed per year at peak capacity than Canopy Growth, is one such name that could thrive internationally. Cannabis industry cheerleader Cowen Group, which has arguably been covering pot stocks longer than any Wall Street investment firm,... | Aurora Cannabis (NYSE: ACB), the only Canadian grower that's expected to produce more weed per year at peak capacity than Canopy Growth, is one such name that could thrive internationally. Cannabis industry cheerleader Cowen Group, which has arguably been covering pot stocks longer than any Wall Street investment firm,... | Aurora Cannabis (NYSE: ACB), the only Canadian grower that's expected to produce more weed per year at peak capacity than Canopy Growth, is one such name that could thrive internationally. For context, Canadian cannabis store sales hit $56.6 million in April, and have tallied just $308.3 million in the first 6.5 months... |
38295.0 | 2019-07-12 00:00:00 UTC | 4 Top Stock Trades for Monday:JNJ, SQ, ILMN, ACB | ACB | https://www.nasdaq.com/articles/4-top-stock-trades-for-monday%3Ajnj-sq-ilmn-acb-2019-07-12 | nan | nan | The stock market is slowly but surely pushing higher. It seems as though the bulls are reluctant to run too far, too fast. At the same time, the bears simply can’t garner any staying power when it comes to pushing this market lower. At least not while rate cuts are on the way. Let’s look at a few top stock trades for n... | ACB is setting up the same descending triangle formation that CGC is and it’s playing out exactly the same. Below the $7 to $7.25 area is very troubling for ACB. If JNJ stock falls down to this level, it may be worth investors nibbling at on the long side. | ACB is setting up the same descending triangle formation that CGC is and it’s playing out exactly the same. Below the $7 to $7.25 area is very troubling for ACB. Top Stock Trades for Monday #1: Johnson & Johnson Shares of Johnson & Johnson (NYSE:) were smacked lower on Friday, falling over 4%. | ACB is setting up the same descending triangle formation that CGC is and it’s playing out exactly the same. Below the $7 to $7.25 area is very troubling for ACB. Top Stock Trades for Monday #1: Johnson & Johnson Shares of Johnson & Johnson (NYSE:) were smacked lower on Friday, falling over 4%. | ACB is setting up the same descending triangle formation that CGC is and it’s playing out exactly the same. Below the $7 to $7.25 area is very troubling for ACB. Top Stock Trades for Monday #2: Square We had Square (NYSE:) on watch for a break higher, and that’s exactly what we’ve gotten this week. |
38296.0 | 2019-07-12 00:00:00 UTC | ‘High’ Caliber: Can Tilray Stock Close the Credibility Gap? | ACB | https://www.nasdaq.com/articles/high-caliber%3A-can-tilray-stock-close-the-credibility-gap-2019-07-12 | nan | nan | A full year after its widely publicized initial public offering, Tilray (NASDAQ:) shares experienced breathtaking highs and gut-wrenching lows. This dynamic attracted a fair share of skeptics and detractors. Even in an already volatile cannabis sector, Tilray stock is a big mover in both directions. Therefore, TLRY isn... | But as it turned out, their fears were unwarranted: Privateer that it wouldn’t sell any of its TLRY shares immediately after the lock-up period expiration. Personally, I feel that this partnership will prove transformative for the cannabis industry; investors and the media practically ignored this landmark arrangement,... | A full year after its widely publicized initial public offering, Tilray (NASDAQ:) shares experienced breathtaking highs and gut-wrenching lows. This most likely caused some investors to panic and sell their holdings of Tilray stock before Privateer could sell theirs. Another boost to Tilray’s credibility is the recent ... | Source: Shutterstock If you’re seeking relative safety in the cannabis stock niche, you’re probably better off sticking with a cannabis old-timer: Speaking relatively, I’m referring to names such as Canopy Growth (NYSE:) or Aurora Cannabis (NYSE:). Another boost to Tilray’s credibility is the recent that they’re import... | But as it turned out, their fears were unwarranted: Privateer that it wouldn’t sell any of its TLRY shares immediately after the lock-up period expiration. Not only that, they’ve to extend their lock-up provision on those TLRY shares for two years. Another boost to Tilray’s credibility is the recent that they’re import... |
38297.0 | 2019-07-11 00:00:00 UTC | Cronos Isn’t in a Rush. Investors in Cronos Stock Shouldn’t Be Either | ACB | https://www.nasdaq.com/articles/cronos-isnt-in-a-rush.-investors-in-cronos-stock-shouldnt-be-either-2019-07-11 | nan | nan | Cronos Group (NASDAQ:) shares have struggled of late. Since early March highs, Cronos stock is down about 35%.
Source: Shutterstock
Cronos stock managed to put together a modest rally last month, but it has faded. CRON sits at a one-month low at the moment.
To be sure, CRON stock isn’t alone. Other cannabis majors are ... | The Canada Problem for Cronos Stock It’s become increasingly clear that the Canadian market isn’t big enough and that there are real worries about too much supply in cannabis flower more broadly. Production in Colombia is focusing on hemp over cannabis, with Gorenstein predicting on the Q1 call that CBD would outpace T... | For the biggest cannabis stocks, investor patience is drying up. The Long-Term Case for Cronos Stock From a long-term standpoint, Cronos’ strategy does seem wise. In a sense, Cronos stock is the pot stock for investors who question whether pot stocks have rallied too far. | The Canada Problem for Cronos Stock It’s become increasingly clear that the Canadian market isn’t big enough and that there are real worries about too much supply in cannabis flower more broadly. The Strategy As CEO Mike Gorenstein put it on the , “Like Altria, we believe that the best way to create value through the s... | To be sure, CRON stock isn’t alone. There’s certainly a risk that while Cronos plays around the edges of the market, rivals like Canopy and Aurora simply overpower the market. In a sense, Cronos stock is the pot stock for investors who question whether pot stocks have rallied too far. |
38298.0 | 2019-07-10 00:00:00 UTC | Aurora Cannabis Stock’s Highs Are Coming | ACB | https://www.nasdaq.com/articles/aurora-cannabis-stocks-highs-are-coming-2019-07-10 | nan | nan | Aurora Cannabis (NYSE:) stock had two recent failed attempts at breaking out from $8 per share. This is a level that has been pivotal since January of 2018 so it’s not a surprise to find it sticky here. But this resistance remains the opportunity for the next few months.
Source: Shutterstock
Clearly the bulls and the b... | But for those who have complete faith in the concept and believe that it’s only a matter of time before the stars will align for pot stocks, they need to simply plug their noses and buy the ACB shares here. But the important thing for the bull thesis is for ACB to hold its support. So in this case I must plot the short... | But the important thing for the bull thesis is for ACB to hold its support. So in this case I must plot the short-term lines that I see here for ACB stock. I need to clarify that the battle though fierce now, year-to-date the ACB is up almost 50%. | Trading ACB Stock If I am already long ACB stock, I just look away for a few months. But for those who have complete faith in the concept and believe that it’s only a matter of time before the stars will align for pot stocks, they need to simply plug their noses and buy the ACB shares here. But the important thing for ... | Trading ACB Stock If I am already long ACB stock, I just look away for a few months. But for those who have complete faith in the concept and believe that it’s only a matter of time before the stars will align for pot stocks, they need to simply plug their noses and buy the ACB shares here. But the important thing for ... |
38299.0 | 2019-07-10 00:00:00 UTC | The New Cannabis ETF Is the Market’s Cheapest Marijuana Fund | ACB | https://www.nasdaq.com/articles/the-new-cannabis-etf-is-the-markets-cheapest-marijuana-fund | nan | nan | Investors that enjoy cannabis investing via the ETF wrapper rejoice: you’ve got another marijuana ETF to consider. On Tuesday, the aptly named Cannabis ETF (NYSEARCA:) came to market.
Source: Shutterstock
The new cannabis ETF’s issuer, Innovation Shares, frames the rookie marijuana fund as the “first passively managed... | Well-known cannabis names in the benchmark include Aurora Cannabis (NYSE:ACB), Canopy Growth (NYSE:) and HEXO Corp (NYSE:), a beaten up Canadian cannabis name. “As a pure-play cannabis ETF, THCX focuses on companies in the legal marijuana, CBD and hemp industries — the portfolio does not rely on alcohol or tobacco stoc... | Well-known cannabis names in the benchmark include Aurora Cannabis (NYSE:ACB), Canopy Growth (NYSE:) and HEXO Corp (NYSE:), a beaten up Canadian cannabis name. “As a pure-play cannabis ETF, THCX focuses on companies in the legal marijuana, CBD and hemp industries — the portfolio does not rely on alcohol or tobacco stoc... | Well-known cannabis names in the benchmark include Aurora Cannabis (NYSE:ACB), Canopy Growth (NYSE:) and HEXO Corp (NYSE:), a beaten up Canadian cannabis name. Source: Shutterstock The new cannabis ETF’s issuer, Innovation Shares, frames the rookie marijuana fund as the “first passively managed pure-play ETF solution f... | Well-known cannabis names in the benchmark include Aurora Cannabis (NYSE:ACB), Canopy Growth (NYSE:) and HEXO Corp (NYSE:), a beaten up Canadian cannabis name. Source: Shutterstock The new cannabis ETF’s issuer, Innovation Shares, frames the rookie marijuana fund as the “first passively managed pure-play ETF solution f... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.